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1The research work incorporated in the thesis with the title “SYNTHESIS AND
CHARACTERISATION OF SOME COMPOUNDS OF MEDICINAL
INTEREST” has been described as under.
Chapter-1 :- STUDIES ON DIHYDROPYRIMIDINES.
Chapter-2 :- STUDIES ON PYRAZOLES.
Chapter-3 :- STUDIES ON DIHYDROPYRIDINES.
Chapter-4 :- STUDIES ON CYANOPYRIDINES.
Chapter-5 :- STUDIES ON QUINOLINES.
Chapter-6 :- STUDIES ON MICROWAVE INDUCED ORGANIC
REACTION  ENHANCEMENT.
Chapter-1 :- STUDIES ON DIHYDROPYRIMIDINES.
Dihydropyrimidine derivatives represent one of the most active classes of
compounds possessing a  wide spectrum of  biological  act ivi t ies  such as
antiinflammatory, antiviral, antibacterial, antitumor, calcium channel blockers,
antihype rtensive agent and anticancer. Many of their derivatives are pharmacologically
important as α1a adrenoceptor selective antagonists.
Dihydropyrimidine nucleus plays an important  role as antiviral and anticancer
agents and they act as fungicide to inhibit ergosterol biosynthesis by inhibiting the
P-450 enzyme.
In order to developing better medicinally important compounds, it was
considered of interest to synthesizese some new dihydropyrimidinone and
dihydropyrimidine thione  derivatives shown as under.
2The thiopyrimidines of type (I) have been synthesized by the condensation of 3-
Aryl-2-isobutanoyl-N-(p-nitrophenyl)-acrylamide and  S-methyl isothiourea.
SECTION-II : Synthesis and biological evaluation of 4-Aryl-6-isopropyl-5-[N-
   (p-nitrophenyl)aminocarbonyl]-3,4-dihydropyrimidine-2(1H) -
    thiones.
The thiopyrimidines of type (II) have been synthesized by the condensation of 4-
Methyl-N-(p-nitrophenyl)-3-oxo-pentanamide, thiourea and aryl aldehydes.
SECTION-III : Synthesis and biological evaluation of 4-Aryl-6-isopropyl-5-[N-(p-
    nitrophenyl)aminocarbonyl]-3,4-dihydropyrimidine-2(1H)-ones.
N
N
H
S
CH3
CH3
R
NH
O
O2N
CH3
NH
N
H
S
CH3
CH3
R
NH
O
O2N
Type (II)                                     R=Aryl
Type (I)                                    R=Aryl
SECTION - I : Synthesis and biological evaluation of 4-Aryl-6-isopropyl-2-
m e t h y l t h i o - 5 - [ N - ( p - n i t r o p h e n y l ) a m i n o c a r b o n y l ] - 1 , 4 -
dihydropyrimidines.
3The oxopyrimidines of Type (III) have been synthesized by the condensation of 4-
Methyl-N-(p-nitrophenyl)-3-oxo-pentanamide, urea and aryl aldehydes.
Chapter-2 :- STUDIES ON PYRAZOLES.
The pyrazole ring is prominent structural motif found in numerous pharmaceuti-
cally active compounds. Due to the rich pharmacological activity, pyrazole framework
plays an essential role in biologically active compounds and therefore represents an
interesting template for combinatorial as well as medicinal chemistry. Indeed pyrazole
based derivatives have shown several biological activities like antiinflammatory, antitu-
mor, antitubercular, amoebicidal, anticonvulsant, hypnotic, CNS depressant.
These findings prompted us to design and synthesize some pyrazole derivatives
possessing better therapeutic values such as pyrazolone and pyrazoline derivatives shown
as under.
SECTION-I : S y n t h e s i s  a n d  b i o l o g i c a l  e v a l u a t i o n  o f   5 - I s o p r o p y l - 2 -
  substituted-2,3-dihydropyrazole-3(1H)-ones.
NH
N
H
O
CH3
CH3
R
NH
O
O2N
 Type (III)                                   R=Aryl
4N NH
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N
CH3
CH3
O
NH
H
H
R
R = Aryl
The pyrazolones  of Type (IV) have been synthesized by the condensation of Me-
thyl-4-methyl-3-oxo-pentanoate and hydrazine derivatives in the presence of gla.acetic
acid.
SECTION-II : Synthesis and biological evaluation of 5-Aryl-3-isopropyl-4-[N-
   phenyl-aminocarbonyl]-4,5-dihydro-1H-pyrazoles.
Type (IV)
The pyrazoline derivatives of Type (V) have been synthesized by the  reaction of
3-Aryl-2-isobutanoyl-N-phenyl-acrylamide with hydrazine hydrate.
Type (V)
R = H ,Aryl
5SECTION-III : Synthesis and biological evaluation of 1-Acetyl-5-aryl-3-isopropyl
    -4-[N-phenyl-aminocarbonyl]-4,5-dihydro-1H-pyrazoles.
N
N
CH3
CH3
O
NH
H
H
R
O
CH3
The pyrazoline derivatives of Type (VI) have been synthesized by the  reaction
of 3-Aryl-2-isobutanoyl-N-phenyl-acrylamide with hydrazine hydrate in gla. acetic acid.
Chapter-3 :- STUDIES ON DIHYDROPYRIDINES.
1,4-Dihydropyridine is the significant subclass of pyridines, the best known
heterocyclic compounds which are associated with  good number of pharmaco-
logical activities. 1,4-Dihydropyridines whether symmetrical or   asymmetrical are
expected for their cardiovascular and other pharmacological properties.
The DHP nucleus is common in numerous bioactive compounds  which include
various vasodilator, antihypertensive, bronchodilator, antiatherosclerotic, hepatoprotec-
tive, antitumor, antimutagenic, geroprotective and antidiabetic agents.
In order to achieving better therapeutic activity we have synthesized some novel
symmetrical dihydropyridines and asymmetrical dihydropyridines  which have been
described as under.
Type (VI) R= Aryl
6SECTION-I : Synthesis and biological evaluation of 4-Aryl-2,6-diisopropyl-3,5-
  bis[N-phenyl-aminocarbonyl]-1,4-dihydropyridines.
N
H
CH3
CH3
O
NH
R
CH3
CH3
NH
O
The dihydropyridines of Type (VII) have been synthesized by the condensation of 3-
Aryl-2-isobutanoyl-N-phenyl-acrylamide and 4-Methyl-3-oxo-N-phenyl-pentanamide
and ammonia.
SECTION-II : Synthesis and biological evaluation of Methyl-4-aryl-6-isopropyl-
   2-methyl-5-[N-phenyl-aminocarbonyl]-1,4-dihydropyridine-
   3-carboxylates.
N
H
CH3
CH3
O
NH
CH3
COOMe
R
The dihydropyridines of Type (VIII) have been synthesized by the condensation
of 3-Aryl-2-isobutanoyl-N-phenyl-acrylamide and Methyl-3-amino-crotonate.
Type (VII)
Type (VIII) R= Aryl
R=Aryl
7Chapter-4 :- STUDIES ON CYANOPYRIDINES.
The emerging role of cyanopyridines in pharmaceutical chemistry  stimulated
tremendous interest in the synthesis of cyanopyridines with therapeutic potential. Cyan-
opyridine derivatives have been reported to be active as antimicrobial, antimalarial, an-
tidiabetic and antihypertensive. Hence, it is pertinent to synthesise some new cya-
nomethoxy pyridine and cyanoethoxy pyridine derivatives possessing better therapeutic
value which have been described as under.
SECTION-I : Sythesis and biological evaluation of 4-Aryl-3-cyano-6-isopropyl-
  2-methoxy-5-[N-phenyl-aminocarbonyl]-pyridines.
N
CH3
CH3
O
NH
O
R
CH3
N
2-Methoxy-3-cyanopyridines of Type (IX) have been synthesized by the
condensation of  3-Aryl-2-isobutanoyl-N-phenyl-acrylamide with malononitrile and
sodium methoxide.
SECTION-II : Sythesis and biological evaluation of 4-Aryl- 3-cyano-2-ethoxy-
             6-isopropyl-5-[N-phenyl-aminocarbonyl]-pyridines.
Type (IX) R= Aryl
8N
CH3
CH3
O
NH
O
R
N
CH3
2-Ethoxy-3-cyanopyridines of Type (X) have been synthesized by the
condensation of 3-Aryl-2-isobutanoyl-N-phenyl-acrylamide with malononitrile and
sodium ethoxide.
Chapter-5 :- STUDIES ON QUINOLINES.
Quinoline and its derivatives have received considerable attention in medicinal
chemistry. The quinoline nucleus is a prominent structural feature in a variety of natural
products as well as in other compounds of medicinal interest. Quinoline derivatives are re-
ported to possess anticonvulsant, tuberculostatic,  hypnotics, sedative, antihypertensive,
antibacterial, antifungal and many other therapeutic activities. Considering the increas-
ing importance of quinoline nucleus, the synthesis of some novel quinoline derivatives
has been under taken.
SECTION-I : Synthesis  and biological  evaluation of 4-(p-Fluorophenyl)-
            2-isopropyl-3-[N-aryl-aminocarbonyl]-quinolines.
Type (X) R= Aryl
9N
F
CH3
CH3
NH
O
R
2-Isopropyl quinolines of  Type (XI)  have been synthesized by the
condensation of 2-Amino-4’-fluoro benzophenone with 4-Methyl-3-oxo-N-aryl-
pentanamide in the presence of methane sulphonic acid.
SECTION-II : Synthesis and biological evaluation of 4-Isopropyl-5,6,7,8-
   substituted quinoline-2(1H)-ones.
N
H
O
CH3CH3
R2
R1
R3
R4
4-Isopropyl quinolines of  Type (XII)  have been synthesized by the
cyclisation of 4-Methyl-3-oxo-N-aryl-pentanamide by concentrated sulphuric acid.
Type (XI)
Type (XII)
R1,R2,R3,R4= H, NO2,
Cl, CH3, OCH3 ...
R= Aryl
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Chapter-6 :- STUDIES ON MICROWAVE INDUCED ORGANIC REACTION
ENHANCEMENT.
Recently reported studies on the use of domestic microwave oven for the
synthesis of heterocycles showed that it is a safe, rapid and convenient methodology.
Keeping in view the substantial reduction in the reaction time with improved yield under
microwave i r radiat ion (MWI),  i t  was thought  worthwhile  to  synthesize
dihydropyrimidinones and dihydropyrimidine thiones under MWI using a microwave oven
as well as in a conventional way.
SECTION-I : Microwave enhanced synthesis of 4-Aryl-6-isopropyl-5-[N-(p-
  nitrophenyl)aminocarbonyl]-3,4-dihydropyrimidine-2(1H)-ones.
NH
N
H
O
CH3
CH3
R
NH
O
O2N
 Type (III)                                   R=Aryl
The oxopyrimidines of Type (III) have been synthesized by the condensation of 4-
Methyl-N-(p-nitrophenyl)-3-oxo-pentanamide, urea and aryl aldehydes.
SECTION-II : Microwave enhanced synthesis of 4-Aryl-6-isopropyl-5-[N-
   (p-nitrophenyl)aminocarbonyl]-3,4-dihydropyrimidine-2(1H)-
   thiones.
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CHARACTERISATION
The constitution of newly synthesized products have been supported by using
elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography.
In vitro study on multiple biological activities.
All the compounds have been evaluated for their antibacterial activity towards
Gram positive and Gram negative bacterial strains and antifungal activity towards A.
niger  at a concentration of 40μg. The biological activity of the synthesized compounds
have been compared with standard drugs.
NH
N
H
S
CH3
CH3
R
NH
O
O2N
Type (II)                                 R=Aryl
The thiopyrimidines of Type (II) have been synthesized by the condensation of
4-Methyl-N-(p-nitrophenyl)-3-oxo-pentanamide, thiourea and aryl aldehydes.
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INTRODUCTION
“SYNTHESIS AND CHARACTERISATION OF SOME COMPOUNDS
OF MEDICINAL INTEREST”
The primary objective of medicinal chemistry is the design and discovery of new
compounds that are suitable for use as drugs. This process requires a team effort. It not
only involves chemists but also workers from a wide range of disciplines such as biol-
ogy, biochemistry, pharmacology, computing and medicine amongst others.
Chemistry related with pharmaceutically important compounds is mainly divided
in two parts. The first, chemotherapy, concerns the treatment of infections, parasites or
malignant diseases by chemical agents, usually substances that shows selective toxicity
towards the pathogen. The other division relates to diseases of bodily dysfunction and
the agents employed are mainly compounds that effect the functioning of enzymes, the
transmission of nerve impulses or the action of hormones on receptors.
Research in the field of pharmaceutical has its most important task in the devel-
opment of new better drugs and their successful introduction into clinical practice.
Central to these efforts, accordingly stand the search for pharmaceutical substances and
preparation which are new and original. In addition to these objectives, we may search
for newer drugs which exhibit some clear advantages over a drug already known. Such
advantages may be qualitative or quantitative improvement in activity, the absence of
undesirable side effects, lower toxicity, improved stability or decreased cost.
Heterocyclic compounds show vital role in the field of pharmaceuticals.  Hetero-
cyclic compounds are used because they have a specific clinical reactivity, for example
epoxides, aziridines and β-lactams. The introduction of heterocyclic group into drugs
13
may affect their physical properties, for example the dissociation constants of sulpha
drugs or modify their patterns of absorption, metabolism or toxicity.
The word ‘drug’ is derived from the French word ‘drogue’ that means a dry
herb. According to “WHO” a drug may be defined as “any substance or product which
is used or intended to be used for modifying or exploring physiological  system or patho-
logical status for the benefit of recipient”.
Drugs action is believed to be due to the interaction of the drug with enzymes,
receptors and other molecules found in the biological system. The binding of a drug to
the active or other sites of an enzyme usually have the effect of preventing the normal
operation of that enzyme. The drug’s therapeutic effect will depend on the stability of
the drug-enzyme complex as well as the fraction of active and    allosteric sites occupied
by the drug. The stronger the binding of the drug to the enzyme and greater the number
of sites occupied, the more effective the drug is likely to be in inhibiting the action of the
enzyme.
The degree of drug activity is directly related to the concentration of the drug in
the aqueous medium in contact with the active or receptor site. The factors affecting this
concentration in a biological system can be classified in to two phase.
(I) The pharmacokinetic phase.
It is concerned with the study of the parameters that control the journey of the
drug from its point of administration to its point of action. It includes the absorption,
distribution, metabolism and elimination of a drug.
(II) The pharmacodynamic phase.
It is concerned with the result of the interaction of drug and body at the receptor
site, that is, what the drug does to the body. This includes physiological and  biochemi-
cal effects of drugs and their mechanism of action at macromolecular /subcellular organ
14
systems.
The role of the medicinal chemist is to design a drug structure that has the maxi-
mum beneficial effects with a minimum of side effects. This design has to take into ac-
count the stereoelectronic characteristics of the target active or receptor site and also
such factors as the drug’s stability in situ, its polarity and its relative solubility in aque-
ous media and lipids. The stereochemistry of the drug is particularly important because
stereoisomers often have different biological   effects that range from inactive to highly
toxic.
In the nineteenth century, chemistry was developed as a science, both in terms of
experimental procedures and scientific theory. Scientist isolated and purified single com-
pound from natural extracts. Methods of organic synthesis were developed that helped
chemists altering structures in a predictable way. The chemists started separating out the
various components of ancient positions to discover whether a single compound was
responsible for the medicinal effect known as the active principle.
A large number of important drugs have been introduced during the period of
1940 to 1960. This period is known as ‘Golden Period’ of new drug discovery. Thus
starting from 1933 the first antibacterial drug prontosil leading to various sulpha drugs;
1940 penicillin, antibiotics; 1945 chloroquine, antimalarial; 1950 methyl dopa, antihy-
pertensive; 1957 chlorthiazide, diuretic; 1958 adrenergic beta blockers coronary va-
sodilator, 1960 semi synthetic penicillin, antibacterial; 1965 trimethoprim, antimicro-
bial; 1967 disodium chromoglycoate, antiallergic; 1972 cimetidine, H2-antagonist 1975
verapamil, calcium antagonist; 1981 captopril, antihypertensive. There are some spe-
cific examples representing new therapeutics.
15
AIMS AND OBJECTIVES
In the pharmaceutical field, there have always been and will continue to be a
need for new and novel chemical inhibitors of biological function. Our efforts are fo-
cused on the introduction of chemical diversity in the molecular frame work in order to
synthesizing pharmacologically interesting compounds of widely different composition.
During the course of our research work, looking to the application of heterocy-
clic compounds, several entities have been designed, generated and characterized using
spectral studies. The details are as under.
¨ To generate several derivatives like dihydropyrimidine, dihydropyridine,
pyrazoline, cyanopyridine, quinoline  bearing β -keto ester nucleus.
¨ To check purity of all the compounds using thin layer chromatography.
¨ To characterize these products for structure elucidation using spectroscopic
techniques like IR, 1H NMR and Mass spectral studies.
¨ To evaluate new products for better drug potential against different strains
of bacteria and fungi.
16
N
N
Ar
E H
X
H
R6 N
E
R6
H
R2
E
Ar
DHPM DHP
E = ester, amide, acyl
R2,R6 = alkyl
X = O, S
Ar = substituted aryl 
(I) (II)
INTRODUCTION
Dihydropyrimidine is the most important member in all the diazines. The chemistry
of pyrimidines and their derivatives has been studied for over a century due to the
association of these systems with a variety of biological properties.  In 1893, the synthesis
of functionalized 3,4-dihydropyrimidin-2(1H)-ones (DHPMs) via multicomponent
reactions (MCRs) of an aromatic aldehyde, urea and ethyl acetoacetate was reported
for the first time by P. Biginelli.1 This efficient approach to partly reduced pyrimidines
was largely ignored in the following decades and therefore, the pharmacological properties
of this interesting heterocyclic scaffold remained unexplored. Since the early 1980s,
however, interest in dihydropyrimidones of Type (I) has increased significantly 2. This
was originally due to the apparent structural similarity of DHPMs to the well known
dihydropyridine calcium channel modulators of the Hantzsch type3 (II). It was soon
established that DHPMs exhibit a similar pharmacological  profile to DHP calcium channel
modulators of the nifedipine type and various activities have been observed in this area
from  1980s to 1990s.4-5
 Recently, the interest in the synthesis of these derivatives has been increased
tremendously because they exhibit promising activities as calciumchannel modulators,
antihypertensive agents, α-1a receptor antagonists and neuropeptide Y (NPY)
antagonists6,7  in anticancer drug capability of inhibiting Kinesinmotor protein.8  Recently,
interest has shifted from DHPM calcium channel modulators to other biologically active
DHPM derivatives, e.g. α1a adrenoceptor selective antagonists which are useful for the
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treatment of benign prostatic hyperplasia 9. Again, the pharmacological activity in the
area of α1a adrenergic antagonists is based on activity found earlier in the DHP series of
compounds. However, dihydropyrimidinones of type (I) represent much more than just
being aza analogs of dihydropyridines of the Hantzsch type (II).
The synthetic strategies for the dihydropyrimidine nucleus involves one-pot to
multi step approaches. The production of dihydropyrimidinones via the well established
Biginelli reaction certainly ranks as one of the most recognize and often used MCRs for
the generation of novel pyrimidine scaffolds.10-13 The use of multicomponent reactions
(MCRs) to generate interesting and novel drug like scaffolds is replete in the recent
chemical literature.14-16 Multicomponent reactions (MCRs) are of increasing importance
in organic and medicinal chemistry.17-22  When a premium is put on speed, diversity and
efficiency in the drug discovery process,20,21 MCR strategies offer significant advantages
over conventional linear type synthesis.17-22
SYNTHETIC ASPECTS
Literature survey reveals that several publications and patents have described the
synthesis of dihydropyrimidines as under.
Over 100 years ago, 4-Aryl-3,4-dihydropyrimidine-2(1H)-ones of type I (DHPMs)
was reported for the first time. In 1893. The Italian chemist Pietro Biginelli discovered a
multicomponent reaction of aldehydes, urea or thiourea and  β-dicarbonyl compounds
that produced these multifunctionalized dihydropyrimidones1  in a simple one pot process.
.
NH2
NH2
O
R
O
O
R1
+
CHO
NH
N
H
OR
O
R1
EthanolH
+
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BUILDING BLOCKS AND CATALYTIC DIVERSITY :
As the earlier examples of this cyclocondensation process typically involved β-
ketoester, aromatic aldehyde and urea, the scope of this heterocyclic synthesis has now
been extended considerably by variation of all three building blocks, allowing access to
a large number of multifunctionalized pyrimidine derivatives.10,12
Diversity of aldehyde building blocks :
Out of the three building blocks in the Biginelli reaction it is the aldehyde
component, which can be varied to the largest extent. In general, the reaction works
best with aromatic aldehydes. These can be substituted in the o, m or p  position with
either electron-withdrawing or donating groups. Aliphatic aldehydes typically provide
only moderate yields in the Biginelli reaction unless special reaction conditions are
employed, i.e. Lewis acid catalysts/solvent free methods or using the aldehydes in
protected form 23. In such transformations, DHPMs having a sugar-like moiety at position
4-(C-nucleoside analogs)(III), (IV) are obtained24,25. In a few cases, bisaldehydes have
been used as synthons Biginelli reactions.26
NH
N
H
O
EtOOC
O
OH
OH
OH
O
OH
OH
OH
H
HH
NH
N
H
O
OHOH
OH
OH
O
EtOOC
CH3
H H
(III) (IV)
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Some of the aldehyde and protected aldehyde building blocks used in the Biginelli reaction
are as under.
NO2
Br
CHO
OMe
MeO
CHO
O
NH
CH3
CH3
CH3
O
OBn
OBn
BnO
BnO
CHO
H
OHC
CHO
OHC
CH3
CHO
Cl
Cl
O CH3
CHO
Diversity of CH- acidic carbonyl building blocks :
Traditionally, simple alkyl acetoacetates are employed as CH-acidic carbonyl
building blocks but other types of 3-oxoalkanoic esters or thioesters can also be used
successfully10.
Li-Wen Xu, et .  al . 27 described a synthesis of  5-unsubstituted 3,4-
dihydropyrimidine-2(1H)-one using acetophenone as a CH-acidic carbonyl and aromatic
aldehyde and urea in the presence of FeCl3–TMSCl as catalyst.
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NH2
NH2 O
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N O
NH
N
H
O
+ +
4-Hydroxycoumarin on reaction with aldehydes in the presence of urea/thiourea
using solid inorganic support under microwave irradiation (MWI) afforded 4-substituted
benzopyrono [4,3-d]- pyrimidine derivatives in a few seconds.28
O O
O
O
R
+
NH2
X
NH2
O
N
H
NH
XR
OMWI
Acidic solid support
Ahmad Shaabani et.  al.29 synthesized Spiro-fused heterocycles  in good to high
yields by a pseudo four-component reaction of an aldehyde, urea and a cyclic β-diester
or α,β-diamide such as Meldrums acid or barbituric acid derivatives using microwave
irradiation under solvent-free conditions.
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Different CH-Acidic carbonyl building blocks used in the Biginelli reaction are  as under.
Diversity of catalyst in the Biginelli synthesis :
The Biginelli condensation is strongly dependent on the amount of acidic catalyst
present in the reaction medium. Traditionally, strong Bronsted acids such as hydrochloric
or sulphuric acid have been employed but nowadays the use of Lewis acids such as
BF3-OEt2 and CuCl 
30, FeCl3
31 or Yb(OTf)3
32 is preferred. In fact a plethora of different
methods and conditions for synthesizing DHPMs according to the Biginelli principle is
known today, ranging from mg to kg scale.33
22
Youquan Deng et, al.34 described a synthesis of 3,4-Dihydropyrimidine-2(1H)-
ones  in high yields by one-pot three-component Biginelli condensation in the presence
of  ionic liquids such as 1-n-butyl-3-methylimidazolium tetrafluoroborate (BMImBF4)
or hexafluorophosphate (BMImPF6) as catalysts under solvent free and neutral conditions
at room temperature.
O
R
X
NH2
NH2CH3 O
O
EtO +
NH
N
H
R
XCH3
O
EtO
X = O,S
ionic liquid
Silica gel supported sodium bisulfite catalyzes efficiently the three component
condensation reaction of aldehyde, β-ketoester and urea in refluxing acetonitrile to afford
the corresponding dihydropyrimidinones.35
O
R
X
NH2
NH2CH3 O
O
EtO +
NH
N
H
R
XCH3
O
EtO
CH3CN . reflux
X = O,S
SiO2-NaHSO4
A simple and green chemistry procedure for the synthesis of dihydropyrimidinones
using heteropolyacid mediated cyclocondensation reaction is as under.36
O
R
X
NH2
NH2CH3 O
O
EtO +
NH
N
H
R
XCH3
O
EtO
X = O,S
HPA
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Diversity of Urea-type building blocks in the Biginelli synthesis :
The urea is the component in the Biginelli reaction that faces the most restrictions
in terms of allowed structural diversity10. Therefore, most of the published examples
involve urea itself as building block. However, simple monosubstituted alkyl ureas
generally react equally well, in a regiospecific manner, to provide good yields of N1-
substituted DHPMs. Thiourea and substituted thioureas follow the same general rules as
ureas, although longer reaction times are required to achieve good conversions. Yields
are comparatively lower than the corresponding urea derivatives. In some instances it is
also possible to react protected urea or thioureas (isoureas) or guanidines of type (V)
under weak basic conditions with the aldehyde and CH-acidic carbonyl component (or
with a precondensed Knoevenagel type enone) to yield the corresponding protected
DHPM37,38. This later method, using precondensed enones of type (VI) has been
frequently referred to as the “Atwal modification” of the Biginelli reaction. 10,12,39
Comparison and diversify analysis of the Biginelli and Atwal dihydropyrimidine
synthesis are as under.
NH
N
R4
XR6
E
R1
N
N
H
R4
XR6
E
R
NH2
NH X
RR4
R6
E
O
(VI)
(V)
R6
E
O
O
R4
O
R4 NH2
NH X
R1
acid
base
base
deprotection
R1,R4,R6 = H,alkyl, (het)aryl
X = O,S,NR
E= ester, amide, acyl, nitro
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MECHANISTIC STUDIES
Since the 1930s several mechanistic pathways have been proposed for the
Biginelli reaction. In 1933, Folkers and Johnson reported that one of three intermedi-
ates (VII-IX) was likely to be present in this  reaction.40
Forty years after the initial proposal, Sweet and Fissekis proposed a more de-
tailed pathway involving a carbonium ion species.41
After 25 years of second proposed mechanism by Sweet and Fissekis, Kappe42
reexamined the same mechanism in 1997 using 1H and 13C NMR spectroscopy to sup-
port the argument that the key step in this sequence involves the acid-catalyzed forma-
tion of an N-acyliminium ion intermediate of type (XI) from the  aldehyde (X) and
urea (XVI) precursors. Interception of the iminium ion (XIII) by ethyl acetoacetate,
presumably through its enol tautomer  produces an open chain ureide  which subse-
quently cyclizes to hexahydropyrimidine(XIV). Acid-catalyzed elimination of water from
(XIV) ultimately leads to the final DHPM product (XV).
NH NH2
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NCH3
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O
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OEt
O
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THERAPEUTIC IMPORTANCE
Dihydropyrimidine derivatives exhibit broad spectrum of therapeutic activities.
Since 1980’s a number of publications and patents are published for the activity of DHPM
derivatives which indicates the interest on the subject is  tremendously  increased.10,12
This is mainly due to the fact that the multifunctionalized dihydropyrimidine scaffold
(DHPM, “Biginelli compounds”)  represents a heterocyclic system with remarkable phar-
macological efficiency. In the past  decades, a broad range of biological effects, includ-
ing antiviral, antitumor, antibacterial and antiinflammatory activities has been described
to these partly reduced pyrimidine derivatives43 Recently, appropriately functionalized
DHPMs have emerged as orally active antihypertensive agents 44,46 or α1a adrenocep-
tor-selective antagonists.47-48  Mayer et al.49-51 have recently identified the structurally
rather simple DHPM (monastrol) as a novel cell-permeable molecule. Monastrol is the
only cell-permeable molecule currently known to specifically inhibit mitotic kinesin Eg5
and can therefore be considered as a leader for the development of new anticancer
drugs. Apart from synthetic DHPM derivatives, several marine natural products with
interesting biological activities containing the dihydropyrimidine-5-carboxylate core have
recently been isolated.52 Most notably among these are the batzelladine alkaloids A and
B  which inhibit the binding of HIV envelope protein gp-120 to human CD4 cells and
therefore  they are potentially new leading molecules  for AIDS therapy.53
Dihydropyrimidines have attracted considerable attention as they appeared with
interest to possess wide range of therapeutic activities. Different activities are as under.
1. Antiviral
54-57
2. Antibacterial
58
3. Antitumor
59-61
4. Cardiovascular
62-64
5. Antiplasmal
65
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6. Anticarcinogenic
66
7. Calcium channel modulator
67-69
8. Antihypertensive
70-72
9. Vasodilative
73
10. Blood platelet aggregation inhibitor
74,75
11. Antiinflammatory
76,77
12. Analgesic
78
13. Antileukemic
79
14. α1a-Adrenergic receptor antagonist.
80,81
15. Coronary dilatory82
16. Anti-ichemic83
17. Neuropeptide Y (NPY) antagonist84
18. Mitotic Kinesin inhibitor85
19. Metabotropic glutamate receptor antagonist86
Dhanapalan N. et al87  prepared dihydropyrimidinones such as compound (XVI)
which exhibited high binding affinity and subtype selectivity for the cloned human α1a
receptor. Systematic modifications of (XVI) led to identification of highly potent and
subtype-selective compounds such as (XVII) with high binding affinity (K1 ) 0.2 nM
for α1a receptor and greater than 1500 fold selectivity over α1b and α1d adrenoceptors.
The compounds were found to be functional antagonists in human, rat and dog prostate
tissues. One compound exhibited excellent to inhibit intraurethral pressure (IUP) as
compared to lowering diastolic blood pressure (DBP) in mongrel dogs Kb(DBP)/
Kb(IUP) = 40 suggesting uroselectivity for α1a-selective compounds
 (XVI) & (XVII).
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Murali et al88  synthesized several DHPM-one analogues. Among these many
compounds give excellent selectivity (>880-fold) over α1b and α1d adrenoceptors also
showed good selectivity over several other recombinant human G-protein coupled
receptors. These compounds showed good functional potency in isolated human prostate
tissues with Kbs comparable to their in vitro α1a binding data. In addition, compound
(+)-(XVIII) also exhibited good uroselectivity (DBP Kb/ IUP Kb > 20-fold) in the in
vivo experiments in dogs.
N
N
H
O
H2N N
H
O
F
O
N
Ph
CN
CH3
F
(XVII)
(XVIII)
James and coworkers89 reported the DHPM with 4-aryl dihydropyrimidinones
attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective α1a receptor
subtype antagonists.  Many of these compounds were also  evaluated in vivo and found
to be more potent than terazosin in both a rat model of prostate tone and a dog model of
intraurethral pressure without significantly affecting blood pressure. While many of the
compounds tested, displayed poor pharmacokinetics, compound (XIX) was found to
have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs.
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Rakesh Kumar and coworkers90 synthesized, 5-substituted-6-azido-5,6-dihydro-
2-deoxyuridine (XX & XXI) and thymidine (XXII & XXIII), which exhibited cytotoxic
and antiviral activities. The compounds (XX) and (XXIII) exhibited a broad spectrum
of antiherpes activity against (HSV-1, HSV-2, HCMV, and VZV).
(XIX)
NH
N
O
OH
N3
X
R
O
OH
OH
R X
H
H
Me
Me
Br
Br
CI
CI
(XX)
(XXI)
(XXII)
(XXIII)
As a demonstration of this new concept in the Biginelli reaction, the synthesis of
two C4 epimer of monastrol analogoues bearing the ribofuranosyl moiety at C-6 position
(XXIV),(XXV),(XXVI) has been synthesized by Alessandro D. et al.91
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(XXIV) (X(XXV)XI)
(XXVI)X
Baldev Kumar et. al.92 have prepared some new oxo-pyrimidine derivative
(XXVII) and reported them as potent calcium channel blockers. Abd. El-Galil and M.
Abdulla93 have synthesized some fused steroidal oxo-pyrimidine derivative (XXVIII)
and reported them as androgenic anabolic agent as well as antiinflammatory agent.
X = O / S / NH
N
H
NH
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COOEt
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NH
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Salvatore B. et al94 studied the stopped-flow fluorometry indicates that monastrol
inhibits ADP release by forming an Eg5-ADP-monastrol complex.
Alessandro95  have studied molecular diversity in DHPM molecules   by introducing
sugar molecules at different position (XXIX) and effect of chirality on activity.
NH
N O
R'OOC
Sugar
Sugar
Sugar
Recently, Vladimir N, Belov et. al.96 have documented enantioselective synthesis
of the novel antiinfective TAN-1057A via aminomethyl-substituted dihydropyrimidinone
heterocycle (XXX).
N
N
H
O NH NH2
O
N
CH3
R
Edward J. et al.97 employ difference in infrared spectroscopy to probable
structural changes that occur in the motor protein with monastrol in the presence of
either ADP or ATP.
(XXX)
(XXIX)
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Various 2-thiopyrimidine derivatives have been synthesized by Sondhi  S.M. et
al.98 One of the compounds Thiazolo[3,2-c]pyrimidine-5-thione derivative (XXXI)
showed good antiinflammatory and analgesic activity. 7-(1-Mercapto-3,3,4a-trimethyl-
4,4a,5,9b-tetrahydro-3H-pyrido[4,3-b]indol-7-yl)-3,3,4a-trimethyl-3,4,4a,5-
tetrahydro-benzo[4,5]imidazo[1,2-c]pyrimidine-1-thiol (XXXII) showed moderate
activity against CDK-1. The other compounds showed moderate antiinflammatory,
analgesic and protein kinase (CDK-5, GSK-3) inhibitory activities.
Rajni Garg et. al.
99
 suggest that the balance of hydrophobicity and a volume-
dependent polarizability plays a key role in the inhibition of the viral protease by these
(XXXIII) inhibitors.
NN
O
OH
R
R
(XXXI)  (XXXII)
  (XXXIII)
NN
NH
NH
N
CH3
CH3
CH3
SH
CH3
CH3CH3
SHNNH
SCH3
CH3
S
CH3
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Several potent, cell permeable 4-aryl-dihydropyrimidinones have been identified
as inhibitors of fatty acid transporter FATP4.  Christopher Blackburn et. al.100 described
that lipophilic ester substituents at the 5-position and substitution at the para-position
(optimal group -NO2 and CF3) of the 4-aryl group led to active compounds
(XXXIV), (XXXV).
N
H
NH
O
O
O
NO2
CH3N
H
NH
O
N
H
O
NO2
CH3
SEt
(XXXIV) (XXXV)
Dennis Russowsky et al.
101
 have reported monastrol was shown to be more active
than its oxo-analogue, except for HT-29 cell line, suggesting the importance of the sulfur
atom for the antiproliferactive activity. Monastrol and the thio-derivatives displayed
relevant antiproliferactive properties with 3,4-methylenedioxy derivative being
approximately more than 30 times potent against colon cancer (HT-29) cell line.
NEW DRUG MOLECULES UNDER CLINICAL STUDY
Recently many new molecules which are under study from phase-I to Phase-IV
clinical trials for different pharmacological action have shown that the basic characteristic
of morpholine to behave as hidden amine has attracted many medicinal chemists to
incorporate this feature in drug design. Some interesting compounds are as under.
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Calcium Channel Blokers102   Anti Hepatitis B Virus Drugs103
Calcium channel blocker104
(XXXV)
Leukotrine Antagonist105
Calcium Channel Blockers106        Antifungal Agent.
Antimalarial Agent.
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With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of dihydropyrimidines which have been
described in following sections.
SECTION-I  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
4-ARYL-6-ISOPROPYL-2-METHYLTHIO-5- [N- (p-
N I T R O P H E N Y L ) A M I N O C A R B O N Y L ] - 1 , 4 -
DIHYDROPYRIMIDINES.
SECTION-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-
ARYL-6-ISOPROPYL-5- [N-p-NITROPHENYL)
AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H) -THIONES.
SECTION-III  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-
ARYL-6-ISOPROPYL-5-[N-(p-NITROPHENYL)
AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-ISOPROPYL-
2-METHYLTHIO-5-[N-(p-NITROPHENYL)AMINOCARBONYL]-1,4-
DIHYDROPYRIMIDINES.
Much interest have been focused around dihydropyrimidine thiones derivatives
because of their wide variety of pharmacological properties and industrial applications.
In view of these findings and achieve to better drug potency, we have synthesized
4-Aryl-6-isopropyl-2-methylthio-5-[N-(p-nitrophenyl)aminocarbonyl]-1,4-di-
hydropyrimidines of Type (I) by the condensation of 3-Aryl-2-isobutanoyl-N-(p-
nitrophenyl)-acrylamide and  S-Methyl isothiourea.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
N
N
H
CH3
CH3
NH
O
S
R
O2N
CH3
R = ArylType I
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Reaction Scheme
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Alkane C – H str.(asym.) 2958.6 2950-2975 108
–CH
3
C – H str. (sym.) 2875.7 2860-2880 "
C – H def. (asym.) 1472.0 1470-1435 "
–C (CH
3
)
2
C – H def. 1386.0 1390-1360 "
Aromatic =C – H str. 3079.1 3090-3030 "
C = C str 1575.7 1584-1573 "
1607.6 1612-1600 "
1404.4 1417-1401 "
C – H i.p. (def) 1274.9 1269-1247 "
1169.7 1181-1171 "
C – H o.o.p. (def) 830.3 832-802 "
Pyrimidine C = C str. 1530.4 1580-1520 109
C – S– C str. 698.0 700-650 "
N – H str. 3398.5 3440-3400 "
C = C str. 1575.7 1580-1550 "
Carboxamide C =O 1651.9 1680-1630 "
N – H str. 3277.2 3380-3150 "
Aromatic Nitro -NO2 1338.5 1370-1300 110
-N=O 1512.1 1550-1510 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
IR SPECTRAL STUDIES OF 6-ISOPROPYL-2-METHYLTHIO-4-PHENYL-5-[N-(p-
NITROPHENYL)AMINOCARBONYL]-1,4-DIHYDROPYRIMIDINE.
N
N
H
CH3
CH3
S
CH3
O
NH
O2N
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NMR SPECTRAL STUDIES OF  6-ISOPROPYL-2-METHYLTHIO-4-PHENYL-5-[N-(p-
NITROPHENYL)AMINOCARBONYL]-1,4-DIHYDROPYRIMIDINE.
Signal
No.
Multiplicity J. value
in Hz
Signal Position
(δ ppm)
Relative No.
of Protons Inference
1. 1.23-1.25 d 6H – HC–(CH
3
)2
2. 2.62 s 3H – S-CH
3
3. 3.42-3.59 m 1H – (CH
3
)2–HC
4. 5.05 s 1H – Prm–CH
5. 7.06-7.60 Overlapped 5H – Ar–H
2d 4H J=7.5, 7.76 Ar–H
6. 8.44 s 1H – N–H
7. 8.89 s 1H – N–H
Internal Standard : TMS; Solvent : DMSO+CDCl3    : Instrument : BRUKER Spectrometer (300 MHz)
N
N
H
CH3
CH3
O
NH
S
CH3
O2N
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ANTIMICROBIAL ACTIVITY
Method : Cup-Plate111
Gram positive bacteria : S. aureus
Bacillus coccus
Gram negative bacteria : P.aeruginosa
Aerogenes
Fungi : A.niger
Concentration           : 40μg
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzoyl Penicillin,
Ciprofloxacin, Erythromycin,
Griseofulvin
The antimicrobial activity was compared with standard drugs like  Amoxicillin,
Benzoyl Penicillin,  Ciprofloxacin, Erythromycin and antifungal activity was compared
with  Griseofulvin. The zones of inhibition were measured in mm.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-ISOPROPYL-
2-METHYLTHIO-5-[N-(p-NITROPHENYL)AMINOCARBONYL]-1,4-
DIHYDROPYRIMIDINES.
(A) Synthesis of 4-Methyl-N-(p-nitrophenyl)-3-oxopentanamide :
A mixture of Methyl-4-methyl-3-oxopentanoate (1.44 gm, 0.01 mol) and
p-nitroaniline (1.38 gm, 0.01 mol) in toluene was refluxed for 12 hrs. with continuous
removal of  low boiling methanol  azeotropically by dean and stark. After completion of
reaction  cool the reaction mixture  to room temp. wash the reaction mixture with dil.
HCl and than with water. Distilled out toluene under vacuum. The resulting residue was
crystalized by the n-Hexane. Yield 55 %, m. p. 980C Anal. Calcd. for C12H14N2O4
Calcd: C, 57.59; H, 5.64; N, 11.19 %, Found:  C, 56.89; H, 5.51; N, 11.05%.
(B) Synthesis of 2-Isobutanoyl-3-phenyl-N-(p-nitrophenyl)-acrylamide :
To the  mixture of Benzaldehyde (1.06gm, 0.01mol) and 4-Methyl-N-(p-
nitrophenyl)-3-oxopentanamide(2.50gm, 0.01mol) in toluene,  morpholine and acetic
acid was added and than the reaction mixture was heated at reflux temp. with continuous
removal of water by dean and stark for 18 hrs. After the completion of the reaction,
cool the reaction mixture to room temp. filter the material and wash with toluene. Make
a slurry of the material into the solution of  sodium meta bisulphite and filter the resulting
pure material under vacuum. Yield 67%, M.P. 156-158oC Anal. Calcd. for C19H18N2O4
Calcd: C, 67.44; H, 5.36; N, 8.28 %, Found:  C, 67.50; H, 5.20; N, 8.30 %.
(C) Synthesis of 6-Isopropyl-2-methylthio-4-phenyl-5-[N-(p-nitrophenyl)
aminocarbonyl]-1,4-dihydropyrimidine :
To the mixture of 2-Isobutanoyl-3-phenyl-N-(p-nitrophenyl)-acrylamide(3.38gm
0.01mol) and isothiourea(2.78gm, 0.01mol) in DMSO, add potassium bicarbonate and
stirr the mixture at the temp. of  45-55oC for 20 hrs. After  completion of the reaction,
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Similarly, other 4-Aryl-6-isopropyl-2-methylthio-5-[N-(p-nitrophenyl)
aminocarbonyl]-1,4-dihydropyrimidines were prepared. The physical data are recorded
in Table No. 1.
(D) Biological evaluation of 4-Aryl-6-isopropyl-2-methylthio-5-[N-(p-
nitrophenyl)aminocarbonyl]-1,4-dihydropyrimidines :
All the compounds have been evaluated for antibacterial and antifungal activity
as described under.
ANTIMICROBIAL  ACTIVITY
It was carried out by cup-plate111 diffusion method which has been described as
under.
(a) Antibacterial activity :
The purified products were screened for their antibacterial activity using
cup-plate agar diffusion method. The nutrient agar broth prepared by the usual method
was inoculated aseptically with 0.5 ml of 24 hrs. old subcultures of B. coccus,
S. aureus , Aerogenes, P.aeruginosa in separate  conical flasks at 35-400C and mixed
well by gentle shaking. About 25 ml content of the flask was poured and evenly spreaded
in a petridish (13 cm diameter) and allowed to set for 2 hrs. The cups (10 mm diameter)
were formed by the help of borer in agar medium and filled with 40mg solution of sample
in DMF).The plates were incubated at 370C for 24 hrs. and the control was also maintained
with 40ug solution of sampie in DMF.The plates were incubated at 37C for 24 hrs and
the control was of DMF in a similar manner and the zones of inhibition of the bacterial
growth were measured in millimeter and recorded in Graphical Chart No. 1
cool down reaction mixture to room temp. Slowly pour the reaction mixture  into a
mixture of crushed ice and dil. HCl and  toluene  stirr the poured mixture for one hr.
separate water layer and adjust pH 9-10 using liq NH3. Filter the material and wash
with water. Purify the material by isopropyl alcohol (IPA). Yield 60% M.P.. 233-235oC
Anal. Calcd. for C21H22N4O3S Calcd: C, 61.44; H, 5.40; N, 13.65 %, Found:  C, 61.23;
H, 5.55; N, 13.61%.
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(b) Antifungal activity :
A. niger  was employed for testing antifungal activity using cup-plate agar diffusion
method. The culture was maintained on sabouraud’s agar slants. Sterilized sabouraud’s
agar medium was inoculated with 72 hrs. old 0.5ml suspension of fungal pores in a
separate flask. About 25 ml of the inoculated medium was evenly spreaded in a petridish
(13cm diameter) and allowed to set for 2 hrs. then cups (10mm diameter) were punched.
The plates were incubated at 30 0C for 48 hrs. After the completion of incubation period,
the zones of inhibition of fungal growth in the form of diameter was measured in mm.
Along the test solution in each petridish one cup was filled up with solvent, which acts as
control. The zones of inhibition of test solutions  are recorded in Graphical Chart No. 1
RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type (I)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=m-
phenoxyphenyl, p-fluorophenyl substituents against B.coccus. The significant activity
was observed in compounds bearing R= m-phenoxyphenyl, o-chlorophenyl, p-
fluorophenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-
45
chlorophenyl, p-nitrophenyl against Aerogenes. In the case of P.aeruginosa all the
compounds were least active except R= p-methoxyphenyl, m,p-dimethoxyphenyl.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
All the compounds were active against A.niger. Maximum activity was shown by the
compounds bearing R=p-fluorophenyl,m,p-dimethoxyphenyl, m-phenoxyphenyl.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was compared with
standard drug like Griseofulvin.
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SECTION-II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-ISOPROPYL-5-
[N-(p-NITROPHENYL)AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H) -THIONES.
Compounds containing pyrimidine ring are widely distributed in nature. Many of
these derivatives are reported to possess different biological activities. In view of these
report, we have synthesized 4-Aryl-6-isopropyl-5-[N-(p-nitrophenyl)aminocarbonyl]-
3,4-dihydropyrimidine-2(1H)-thiones of Type (II) by the condensation of 4-Methyl-N-
(p-nitrophenyl)-3-oxo-pentanamide, thiourea and aryl aldehydes in the presence of
catalytic  amount of con. HCl.
NH
N
H
CH3
CH3
NH
O
S
R
O2N
R = ArylType II
The structure elucidation of synthesized compounds has been done on the basis
of elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40 μg. The biological activities
of synthesized compounds were compared with standard drugs.
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CH3
CH3
O
OMe
O
NH2
O2N
+
CH3
CH3
O
O
NHO2N
NH
N
H
CH3
CH3
O
NH
O2N
S
R
O
R
+ S
NH2
NH2
H+
Ethanol
R= Aryl
Toluene
Reaction Scheme
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Alkane C – H str.(asym.) 2959.8 2975-2950 108
–CH
3
C – H str. (sym.) 2858.8 2880-2860 "
C – H def. (asym.) 1472.3 1470-1435 "
–C (CH
3
)
2
C – H def. 1381.0 1390-1360 "
Aromatic =C – H str. 3070.6 3090-3030 "
C = C str 1609.5 1612-1600 "
1402.3 1417-1401 "
C – H i.p. (def) 1258.5 1269-1247 "
1178.9 1181-1171 "
1111.7 1124-1110 "
C – H o.o.p. (def) 820.1 832-802 "
Pyrimidine C = C str. 1542.3 1580-1520 109
C = S str. 1301.0 1300-1100 "
N – H str. 3399 3440-3400 "
Carboxamide C =O 1661.2 1680-1630 "
N – H str. 3272.7 3380-3150 "
Aromatic Nitro -NO2 1334.1 1370-1300 110
-N=O 1509.2 1550-1510 "
Ether Ar-O-C 1209.5 1260-1200 "
IR SPECTRAL STUDIES OF 6-ISOPROPYL-4-(p-METHOXYPHENYL)-5-[N-(p-NITROPHENYL)
AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-THIONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
NH
N
H
CH3
CH3
O
NH
S
O2N
O
CH3
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NMR SPECTRAL STUDIES OF 6-ISOPROPYL-4-PHENYL-5-[N-(p-NITROPHENYL)
AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-THIONE.
1. 1.77-1.52 d 6H – HC–(CH3)2
2. 3.84 m 1H – (CH3)2–CH
3. 5.60-5.59 s 1H _ pyrm–CH
4. 7.05-7.56 Overlapped 5H – Ar–H
2d 4H J=8.4, 8.5 Ar–H
5. 8.42 s 1H – –NH
6. 8.63 s 1H – –NH
7. 8.73 s 1H – –NH
Internal Standard : TMS; Solvent : CDCl3+DMSO  : Instrument : BRUKER Spectrometer (300 MHz)
Signal
No.
Multiplicity J. value
in Hz
Signal Position
(δ ppm)
Relative No.
of Protons Inference
NH
N
H
CH3
CH3
O
NH
S
O2N
52
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-ISOPROPYL-5-
[N-(p-NITROPHENYL)AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-THIONES.
(A) Synthesis of 4-Methyl-N-(p-nitrophenyl)-3-oxopentanamide :
See chapter-I, section-I (A), Page No. 42.
(B) Synthesis of  6-Isopropyl-5-[N-(p-nitrophenyl)aminocarbonyl]-4-phenyl-3,4-
dihydropyrimidine-2(1H)-thione :
A mixture of thiourea (0.76 gm, 0.01 mol), benzaldehyde (1.06 gm, 0.01 mol)
and 4-Methyl-N-(p-nitrophenyl)-3-oxo-pentanamide (2.50 gm, 0.01 mol) in 15 ml of
ethanol containing few drops of concentrated hydrochloric acid was refluxed for 8 hrs.
The solution was allowed to stand for 12 hrs. at room temperature and the resulting
solid mass separated was filtered and crystalized from dioxane. Yield 45%, M.P. 2470C,
Anal. Calcd. for C20H20N4O3 S    Calcd: C, 63.15; H, 5.30; N, 14.13 %, Found:
C, 63.09; H, 5.25; N, 14.18 %.
Similarly, other 4-Aryl-6-isopropyl-5-[N-(p-nitrophenyl)aminocarbonyl]-3,4-
dihydropyrimidine-2(1H)-thiones were prepared. The physical data are recorded in Table
No. 2.
(C) Biological  evaluation of  4-Aryl-6- isopropyl-5-[N-(p-nitrophenyl)
aminocarbonyl]-3,4-dihydropyrimidine-2(1H)-thiones :
Antimicrobial testing was carried out as described in chapter-I, section-I(D),
Page No. 43. The zones of inhibition of test solutions are recorded in Graphical Chart
No.2.
EXPERIMENTAL
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type (II)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However, comparatively significant activity was observed in compounds with R=o-
hydroxyphenyl, p-fluorophenyl substituents against B.coccus. Compounds bearing R=
o-hydroxyphenyl, m-nitrophenyl have fairly inhibit the growth of S.aureus.
The maximum activity was displayed by the compounds bearing R= o-
hydroxyphenyl, p-fluorophenyl against Aerogenes. Almost all  compounds were found
mildly active against P.aeruginosa while the compounds bearing R= o-hydroxyphenyl,
p-fluorophenyl.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
All the compounds were active against A. niger. Maximum activity was shown by the
compounds bearing  R=o-hydroxyphenyl, p-fluorophenyl.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was compared with
standard drug like Griseofulvin.
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The broad spectrums of pharmacological properties have been demonstrated by
the dihydropyrimidinones nucleus. Inspired by these facts, novel dihydropyrimidinone
derivatives of Type(III) have been synthesized by the condensation of 4-Methyl-N-
(p-nitrophenyl)-3-oxo-pentanamide, urea and aryl aldehydes in the presence of catalytic
amount of con. HCl.
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-ISOPROPYL-5-
[N-(P-NITROPHENYL)AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONES.
SECTION-III
NH
N
H
CH3
CH3
NH
O
O
R
O2N
R = ArylType III
The structure elucidation of synthesized compounds has been done on the basis
of elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
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CH3
CH3
O
OMe
O
NH2
NO2
+
CH3
CH3
O
O
NHO2N
NH
N
H
CH3
CH3
O
NH
O2N
O
R
O
R
+
R= Aryl
Toluene
H+
EthanolNH2
O
NH2
Reaction Scheme
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Alkane C – H str.(asym.) 2926.4 2975-2950 108
–CH3 C – H str. (sym.) 2856.4 2880-2860 "
–C (CH3)2 C – H def. 1389.6 1390-1360 "
Aromatic =C – H str. 3076.6 3090-3030 "
C = C str 1617.8 1612-1600 "
1409.8 1417-1401 "
C – H i.p. (def) 1252.5 1269-1247 "
1168.48 1181-1171 "
1109.9 1124-1110 "
C – H o.o.p. (def) 829.6 832-802 "
Pyrimidine C = C str. 1560.3 1580-1520 109
C = O str. 1698.3 1660-1700 "
N – H str. 3410.0 3440-3400 "
Carboxamide C =O 1660.8 1680-1630 "
N – H str. 3343.5 3380-3150 "
Aromatic Nitro -NO2 1332.5 1370-1300 110
-N=O 1504.1 1550-1510 "
Ether Ar-O-C 1210.0 1260-1200 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
IR SPECTRAL STUDIES OF 6-ISOPROPYL-4-(p-METHOXYPHENYL)-5- [N-(p-
NITROPHENYL)AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-ONE.
NH
N
H
O
CH3
CH3
O
NH
O2N
O
CH3
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Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons Inference
1. 1.45-1.63 d 6H CH–(CH3)2
2. 3.29-3.41 m 1H (CH3)2–CH
3. 4.84-4.86 s 1H Pyrm-CH
4. 7.13-7.62 Overlapped 8H Ar–H
5. 8.88 s 1H N–H
6. 9.05 s 1H N–H
7. 9.89 s 1H N–H
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (300 MHz)
NH
N
H
CH3
CH3
O
NH
O
O2N
NO2
NMR SPECTRAL STUDIES OF 6-ISOPROPYL-4-(p-NITROPHENYL)-5-[N-(p-NITROPHENYL)
AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-ONE.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-ISOPROPYL-5-
[N-(p-NITROPHENYL)AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONES.
(A) Synthesis of 4-Methyl-N-(p-nitrophenyl)-3-oxopentanamide :
See chapter-I, section-I (A), Page No. 42.
(B) Synthesis of  6-Isopropyl-4-(p-nitrophenyl)-5-[N-(p-nitrophenyl)
aminocarbonyl]-3,4-dihydropyrimidine-2(1H)-one :
A mixture of urea (0.60 gm, 0.01 mol), p-Nitro benzaldehyde (1.51 gm, 0.01
mol) and 4-Methyl-N-(p-nitrophenyl)-3-oxo-pentanamide (2.50 gm, 0.01 mol) in 15
ml of methanol containing few drops of concentrated hydrochloric acid was refluxed for
8 hrs. The solution was allowed to stand for 12 hrs. at room temperature and the resulting
solid mass separated was filtered and crystalized from dioxane. Yield 41%, M.P..
251 0C, Anal. Calcd. for C21H19N5O6 Calcd: C, 56.47; H, 4.50; N, 16.46 %, Found:
C, 56.50; H, 4.43; N, 16.34 %.
Similarly, other 4-Aryl-6-isopropyl-5-[N-(p-nitrophenyl)aminocarbonyl]-3,4-
dihydropyrimidine-2(1H)-ones were prepared. The physical data are recorded in Table
No. 3.
(C) Biological evaluation of 4-Aryl-6-isopropyl-5-[N-(p-nitrophenyl)
aminocarbonyl]-3,4-dihydropyrimidine-2(1H)-ones :
Antimicrobial testing was carried out as described in chapter-I, section-I(D),
Page No. 43. The zones of inhibition of test solutions are recorded in Graphical Chart
No.3.
EXPERIMENTAL
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type
(III) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However the maximum activity was observed in compounds bearing R=p-hydroxy-
m-methoxyphenyl, o-hydroxyphenyl substituents against B.coccus. The significant activity
was observed in compounds bearing R= o-chlorophenyl, m,p-dimethoxyphenyl against
S.aureus.
The maximum activity was displayed by the compounds bearing R= p-hydroxy-
m-methoxyphenyl, p-chlorophenyl, p-fluorophenyl against Aerogenes. In the case of
P.aeruginosa all the compounds were least active except R= p-fluorophenyl, p-
chlorophenyl.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
The significant activity was observed in compounds having R=p-methylphenyl, p-
fluorophenyl and p-methoxyphenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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INTRODUCTION
Pyrazoles are well known five membered heterocyclic compounds and several
procedures for its synthesis have been extensively studied. Such studies have been
stimulated by various promising applications, especially in the case of N-substituted
pyrazole derivatives. In fact, certain N-substituted pyrazoles are used as analgesic,
antiinflammatory, antipyretic, agrochemicals whereas some others are being studied for
their medicinal interest.
The knowledge of such applications has pointed out that N-substituted pyrazoles
are important target to be prepared to our interest on synthesis and molecular structure
determination of some types of pyrazoles.
The pyrazole ring system  consists of a doubly unsaturated five membered ring
containing two adjacent nitrogen atoms.
The discovery of pyrazole derivatives as antipyretic agents dates back to 1884,
when the German chemist Ludwig Knorr1 attempted to synthesize quinoline derivatives
with antipyretic activity and accidentally obtained antipyrine (2,3-Dimethyl-1-phenyl-
3-pyrazolin-5-one), which has analgesic, antipyretic and antirheumatic activity.
Aminopyrine, a more potent analogue was synthesized there after and these drugs were
widely used in market as antipyretics. In pyrazole ring if one carbonyl grop comes at 5
position it is known as pyrazolone. The pyrazolone exists as a mixture of the three most
probable tautomeric structures. Pyrazolone has been extensively explored for its impor-
tance in the field of pharmaceutical development. This five member heterocyclic ring has
attracted attention word wide.
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Pyrazoles and their reduced forms pyrazolines are well known nitrogen containing
five membered heterocyclic compounds which possess widespread chemical and
pharmacological applications2-4 such as analgesic, antipyretic and antirheumatic.5,6  These
derivatives are also well known for their pronounced anti-inflammatory properties7,8  and
are used as potent antidiabetic agents.9,10 In addition, the pharmacological and antitumor
activities of many compounds containing pyrazoline rings have been reviewed.11-13
Pyrazolines can  be synthesized from α,β-unsaturated carbonyl compounds and
hydrazines. They are reported to be potential extractants and powerful drugs.14 The
chemistry of pyrazoline was reviewed by Jorbe in 1967, which have been studied
extensively for their biodynamic behaviour15 and industrial applications.16
N
N
R3R2
R1
R
SYNTHETIC ASPECTS
Synthetic aspect for Pyrazolone.
Different methods are reported in literature for the preparation of pyrazolone
some are as under.
1. By the reaction of ethyl acetoacetate with hydrazines.17-19
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2. By the reaction of methyl esters of alkylacetylenecarboxylic acids with
alkylhydrazines this appears to be 1,3-dialkyl-5-pyrazolone.20-23
3. Suzanne Gelin et al.24  described the synthesis of 5-pyrazolone in which the
rearrangement of phenylhydrazones of 3-Acyl-pyran-2,4(3H)-dione was refluxed in acetic
acid to give  4-Acylacetyl-l-phenyl-4(H)-5-pyrazolones.
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4. Pyrazolone derivatives were synthesized by Jan Pawlas et al.25 by the treatment
of concentrated sulphuric acid on N-hydroxy pyrazole derivatives with methanol as a
neucleophile.
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5. The pyrazolone synthesis is described by Chang-Kyu Kim et al.26 with the
cyanoacetanilide starting material. The cyanoacetanilide is first reacted with hydroxy-
lamine to give amidoxime, which was acetylated with acetic anhydride the resulting acety-
lated amidoxime was than cyclized on heating in a high boiling solvent to afford 1,2,4-
oxadiazole.This was then treated with base to give 3-Acetylamino-l-(2,4,6-
trichlorophenyl)-2-pyrazolin-5-one which on Hydrolysis gives title compound 3-Amino-
l-(2,4,6-trichlorophenyl)-2-pyrazolin-5-one.
6. Robert K. Boeckman et al.27 described a novel Pd(0)-catalyzed carbonylation of
both isolable 1,2-diaza-1,3-butadienes and those generated in situ by extrusion of SO2
and CO2 from heterocyclic precursors. The reaction proceeds at room temperature to
110 °C under 1-2 atm. of CO to afford 2,3-pyrazol-1(5H)-ones.
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REACTION MECHANISM
The mechanism of the formation of pyrazolone is illustrated as under.28
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Different methods for the preparation of 2-pyrazoline derivatives documented in
literature are as follows.
1. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones with
hydrazine hydrate.29
Synthetic aspect for pyrazoline.
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5. Dipolar cycloaddition of nitrile imines of dimethyl fumarate, fumaronitrile and the
N-aryl maleimides yielded the corresponding pyrazolines.34
6. Pyrazoline was constructed by treating a THF solution of diethyl azodicarboxylate
(DEAD)  and Ethyl-2-(4-nitrobenzyl)-2,3-butadienoate with a stoichiometric
quantity of triphenylphosphine at reflux temperature.35
2. 2-Pyrazolines can be prepared by condensation of chalcone dibromide with
hydrazines.30
3. Epoxidation of chalcones gave epoxy ketones which reacts with hydrazine and
phenyl hydrazine to give pyrazolines.31,32
4. 2-Pyrazolines can be prepared by cyclocondensation of γ-ketosulfone with
refluxing hydrazines and KOH/methanol under nitrogen condition.33
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8. α-Substituted α,β-unsaturated ketones  were treated with hydrazine hydrate  to
yield pyrazolines.36
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9. The pyrazoline bisphosphonate was prepared by the cyclocondensation of
tetra ethyl vinylidenebisphosphonate with diazoketones in ether at room
temperature.37
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Furthermore, B. Gyassi et al.38 investigated the one pot synthesis of some
pyrazolines in dry media under microwave irradiation. S. Paul et al.39 and Dandia Anshu
et al.40 have also described the microwave assisted synthesis of 2-pyrazolines.
REACTION MECHANISM
The following mechanism seems to be operable for the condensation of chalcones
with hydrazines.41
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Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system (I) forms species (II), in which the negative charge is mainly accomodated by the
electronegative oxygen atom. Proton transfer from the nitrogen to oxygen produces an
intermediate and which simultaneously ketonises to ketoamine (III). Another
intramolecular nucleophillic attack by the primary amino group of ketoamine on its
carbonyl carbon followed by proton transfer from nitrogen to oxygen leads  ultimately
to hydroxyl amine (IV). The later with a hydroxy group and amine group on the same
carbon loses water easily to yield the pyrazolines(V).
THERAPEUTIC  IMPORTANCE
Antipyrine(2,3-dimethyl-1-phenyl-3-pyrazolin-5-one), was the first pyrazolone
derivative used in the management of pain and inflammation. Research devoted to the
development of new analgesic agents of this series led to the discovery of aminopyrine
and dipyrone. In an effort to increase analgesic properties and decrease adverse effects
pyrazolidinedione derivatives, phenylbutazone and its potent metabolite oxyphenbutazone
were synthesized. The synthesis and therapeutical studies of pyrazolones and their
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derivatives were undertaken by several groups of workers.42-46
Pyrazolone derivatives exhibit broad spectrum of therapeutic activities. The
several biological activities associated with pyrazolone have been described as under.
1. Antitumor.47
2. Antiulcer.48
3. Antibacterial.49
4. Anticancer.50
5. Neurotonsin receptor antagonist.51
6. Lipoxygenase inhibitor.52
7. Parasitical.53
8. Antiinflammatory.54
9. Antitubercular.55
10. Antidiabetic.56,57
11. Immunosuppressive.58
12. α1a and α2a adrenosine binding activities.
59
13. Leukotriene inhibitors.60
14. Cardiac disorder.61
15. Coagulation factor.62
16. Antiinfective.63
17. Organ transplantation.64
18. Antibiotics.65
Takashima Y. et. al.66  have synthesized some pyrazolone derivatives showing
herbicidal activity. Akahane A. et al.67 have synthesized pyrazolone derivatives were
found to be active against of ischemic heart disease. Rajeev et al.68 have prepared pyra-
zolone derivatives (I) and reported as potent antimicrobial agent.
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Nakamura K. et al.69 have synthesized some pyrazolone derivatives and found to
be Cox-II inhibiting agents useful for the treatment and prevention of inflammatory con-
ditions, collagen diseases, antiimmune disease, thrombosis and cancer or neurodegen-
erative diseases.
Yoshikuni et. al.70 and Bratusek et. al.71  have synthesized 3-Methyl-5-oxopyrazole
derivatives of type (VI) and (VII) respectively and evaluated their biological activity.
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Nakatshuka M. et. al72  have assessed pyrazolone as immunosuppressant. Banks
B. J. et al.73 have prepared pyrazolone derivatives which were active as antiparasitic
agents.
Salman, A. S. S. et al74  have prepared some novel pyrazolone derivative (VIII)
which showed antimicrobial activity. Sharma V. and Khan M. S. Y.75  have synthesized
pyrazolone derivative (IX) which were found to be active as non steroidal antiinflamma-
tory drug.
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THERAPEUTIC IMPORTANCE OF PYRAZOLINES
Compounds with a pyrazole structure are known to possess monoamine oxidase
inhibitor76,  antibacterial77,  antidepressant78,  hypotensive79,  antipyretic and
antiinflammatory80 activities. Pyrazolines, bicyclic pyrazolines  are nitrogen containing
heterocyclic compounds are well known for their pronounced antiinflammatory
activity.81-89  These compounds have been developed as nonsteroidal antiinflammatory
drugs. They block the formation of prostaglandins and having analgesic, antipyretic and
antiinflammatory activity.90 The discovery of this class of drugs provides an outstanding
case history of modern drug development and also points out the unpredictability of
biological activity from structural modification of a prototype drug molecule.
From the literature survey, it was revealed that 2-pyrazolines are better therapeutic
agents. Some of the activities are mentioned below.
1. Antiallergic.91
2. Anticonvulsant. 92,93
3. Antiimplantation.94
4. Antiinflammatory.95
5. Antitumor.96
6. Antineoplastic.97
7. Antimicrobial.98
8. Analgesic.99,100
9. Bacteriocidal.101,102
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10. Cardiovascular.103
11. Diuretic.104
12. Fungicidal.105
13. Hypoglycemic.106
14. Tranquilizer.107
Untawy, Atif and coworkers
108
 have patented 3-Methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agent. K. Satyanarayana and MNA Rao109
synthesized some 4-[5-(substituted aryl)-4,5-dihydro-lH-pyrazol-3-yl]-3-phenyl
sydnones(XI) as antiinflammatory, antiarthritic and analgesic agents. Essa H. Hu et al.110
have synthesized some pyrazoline derivatives (X) of anthranilic acid and reported them
as antiinflammatory agents.
(X)
N
S
N
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COOH
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N N
R
COCH3
R = -C6H5
= -p-OCH3-C6H4
= -p-OH-C6H4
Parikh et. al.111  have synthesized some antimicrobial pyrazolines. Shivananda
M. K. and co-workers112   have prepared substituted pyrazolines and reported their
antibacterial activity. Guniz Kacukguzel et al.113  have synthesized pyrazolines as a
antimicrobial and anticonvulsant agents. Gulhan T. Z. and co-workers 114 have prepared
pyrazolines as a hypotensive agent. Nisha Singh and co-workers 115 have synthesized 1-
acetyl pyrazolines (XII) and reported them as potent pesticides and fungicides.
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E. Palaska et al.116 have prepared 3,5- diphenyl-2-pyrazolines (XIII) and cited
their antidepressant activity. Malhotra V. et al.117   have synthesized new pyrazolines as
a cardiovascular agents (XIV).
(XIV)
R1 =H, Cl, Br, Me, MeO
R2 = H, Cl
R1, R2 = Aryl
N NH
R1 R2
OMe
OMe
NN
Ph R1
NH
S
R2
Tejas Upadhyay et. al.118  and Sohit Rajvaidya et. al.119 have prepared pyrazolines
as antimicrobial agent. Ashok Kumar et al.120 have synthesized pyrazolines as
anticonvulsant agents (XV).
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A. V. Dobaria and co-workers121 have discovered pyrazolines bearing
chloroquinoline nucleus as antimicrobial agents (XVI). Berghot M. A. et. al.122 have
prepared some pyrazoline derivatives of diazepam having antibacterial activity.
NCH3 Cl
N
H
N
R
R = Aryl(XVI)
Ahn J. H. et. al.123 have described the synthesis of cyano-pyrazoline derivatives
as potent antidiabetic agents (XVII) and DP-IV inhibitor activity.  Jeong T. S. et. al.124
have synthesized some novel 3,5-diaryl pyrazolines as human acyl-Co A: cholesterol
acyl transferase inhibitors.
N NH
NH
N
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N
NC
CN
(XVII)
Novel analogs of linezolid (XVIII) were synthesized by Stan D. Andrea,et. al.125
and evaluated their antibacterial activity.
N
N N
O
O
F
NH
Ac
(XVIII)
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Y. Rajendra Prasad et. al.126 have synthesized some 1,3,5-triphenyl-2-pyrazolines
and 3-(2’-hydroxy naphthalen-1’-yl)-1,5-diphenyl-2-pyrazolines and reported as
antidepressant (XIX) & (XX).
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NN
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1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines(XXI) were
synthesized  by Gulberk Ucar et al.127 A novel cholinesterase and selective monoamine
oxidase B inhibitors for the treatment of Parkinson’s and Alzheimer’s diseases.
(XXI)
Fedele Manna128 and co workers synthesized substituted pyrazoline (XXII)  and
evaluated for their anticancer activity and for their ability to inhibit P-glycoprotein
mediated multidrug resistance by direct binding to a purified protein domain containing
an ATP-binding site and a modulator interacting region.
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D. G. Jones et al.129 have synthesized pyrazoline derivative(XXIV) which
possessing PR antagonist activity. Amir Azam and co-workers130  have synthesized some
1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives(XXIII) and tested
their antiamoebic activity.
(XXII)
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Mohammad Abid and Amir Azam131 have synthesized 1-(thiazolo[4,5-
b]quinoxalin-2-yl)-3-phenyl-2-pyrazoline derivatives (XXV) and reported as antiamoebic
agent.   John R. Goodell. et al.132 have synthesized novel 1,3,5-trisubstituted pyrazoline
derivative which shows anti west nile virus activity (XXVI).
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Abd El-Gal i l  E.  Amr et .  a l . 133 synthesized a  ser ies  of  androstano
[17,16c]pyrazolines (XXVII). The compounds were evaluated for their antiandrogenic
activity compared to that of Cyproterone.
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M. Shaharyar et al.134   the pyrazolines (XXVIII) were synthesized and  tested for
their antitubercular activity in vitro against Mycobacterium tuberculosis H37Rv (MTB)
and INH-resistant M. tuberculosis. (INHR-MTB).
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Richard A. Nugent,et al.37  synthesize pyrazoline bisphosphonate esters (XXIX)
which  showed  novel antiinflammatory activity and are capable of inhibiting chronic
arthritis and inflammation in animals. Such compounds might be useful in man for treating
chronic tissue injury associated with arthropathies such as inflammatory joint disease as
well as other chronic inflammatory diseases. A novel pyrazoline (XXX) compound that
has potent cerebroprotective effects in the rat focal cerebral ischemia model was
discovered by H. Kawazural,et al.135 David M. Ferguson and Pei-Yong Shi.136
Synthesized Triaryl pyrazoline {[5-(4-chloro-phenyl)-3-thiophen-2-yl-4,5-dihydro-
pyrazol-1-yl]-phenyl-methanone}(XXXI) inhibits flavivirus infection in cell culture. The
inhibitor was identified through high-throughput screening of a compound library using a
luciferase-expressing West Nile (WN) virus infection assay.
NN
H
O
P
P
EtO
EtO
O
O
EtO
EtO
F
(XXIX)
N
NCH3
N O
(XXX)
N N
O
S
Cl
(XXXI)
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Literature survey reveals that the compounds bearing pyrazole moiety possess
potential drug activity. Looking to the diversified biological activities we have synthesized
some pyrazole derivatives in order to achieving better therapeutic agents. These studies
are described in following parts.
SECTION-I  : SYNTHESIS  AND BIOLOGICAL EVALUATION
O F   5 - I S O P R O P Y L - 2 - S U B S T I T U T E D - 2 , 3 -
DIHYDROPYRAZOLE-3(1H)-ONES.
SECTION-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-
ARYL-3-ISOPROPYL-4-[N-PHENYL-AMINOCARBONYL]-
4,5-DIHYDRO-1H-PYRAZOLES.
SECTION-III  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-
ACETYL-5-ARYL-3-ISOPROPYL-4- [N-PHENYL-
AMINOCARBONYL]-4,5-DIHYDRO-1H-PYRAZOLES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF  5-ISOPROPYL-2-
SUBSTITUTED-2,3-DIHYDROPYRAZOLE-3(1H)-ONES.
Pyrazole derivatives  play a vital role owing of their wide range of biological
activity and with an aim to getting better drug, it was considered worthwhile to synthesize
some new  pyrazole derivatives of Type (IV). The preparation of  5-Isopropyl-2-
subs t i tu ted-2 ,3-d ihydropyrazole-3(1H)-ones  have  been under taken by
cyclocondensation of Methyl-4-methyl-3-oxo-pentanoate and hydrazine derivatives in
the presence of gla. acetic acid.
N NH
O
CH3
CH3
R
R= H, ArylType (IV)
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40mg. The biological activities
of synthesized compounds were compared with standard drugs.
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CH3
CH3
O
OMe
O
+ NH
NH2
R
N
NH
CH3
CH3
R
O
gla. acetic acid
R= H, Aryl
Reaction Scheme
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Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
 
Alkane C – H str.(asym.) 2967.5 2975-2950 108
–CH3 C – H str. (sym.) 2884.3 2880-2860 "
–C (CH3)2 C – H def. 1392.6 1390-1360 "
Aromatic =C – H str. 3069.8 3090-3030 "
C – H i.p. (def) 1252.5 1269-1247 "
1173.1 1181-1171 "
C – H o.o.p. (def) 828.4 832-802 "
pyrazolone C=C 1666.1 1670-1600 110
C =O 1702.2 ~ 1705 "
N – H str. 3393.8 3300-3500 "
N
NH
CH3
CH3
O
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc)
IR SPECTRAL STUDIES OF 5-ISOPROPYL-2-PHENYL-2,3-DIHYDRO-PYRAZOLE-3-(1H)-ONE.
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NMR SPECTRAL STUDIES OF 5-ISOPROPYL-2-PHENYL-2,3-DIHYDRO-PYRAZOLE-3-(1H)-
ONE.
N
NH
CH3
CH3
O
Internal Standard : TMS; Solvent : DMSO   : Instrument : GEMINI-2000 Spectrometer (200 MHz)
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons
1. 1.17-1.20 d 6H CH–(CH3)2
2. 2.71-2.81 m 1H (CH3)2–CH
3. 5.38 s 1H pyrz–H
4. 7.15-7.73 m 5H Ar–H
5. 11.42 s 1H N–H
Inference
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF  5-ISOPROPYL-2-
SUBSTITUTED-2,3-DIHYDROPYRAZOLE-3(1H)-ONES.
(A) Synthesis of 5-Isopropyl-2-phenyl-2,3-dihydro-pyrazole-3-(1H)-one :
Take a mixture of Methyl-4-methyl-3-oxo-pentanoate (1.44 gm, 0.01 mol) and
phenyl hydrazine (1.08gm, 0.01mol) into the methanol, add glacial acetic acid 2-5 drops
to it and heat the reaction mass at 70-80oC for 1hr. cool and pour into the ice, filter the
product and wash with water, dry it and purify into isopropyl alcohol .Yield 62%  m.p.
72-75oC Anal.Calcd. for    C12H14N2O  Calcd: C, 71.26; H, 6.98; N, 13.85 %, Found:
C, 71.24; H, 6.96; N, 13.82%.
Similarly, other 5-Isopropyl-2-substituted-2,3-dihydropyrazole-3(1H)-ones were
prepared. The physical data are recorded in Table No.4.
(B) Biological evaluation of  5-Isopropyl-2-substituted-2,3-dihydropyrazole-
3(1H)-ones :
Antimicrobial activity was carried out as described in chapter-I, section-I (D),
Page No.43. The zones of inhibition of the test solutions are recorded in Graphical
Chart No. 4.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of Type
(IV) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
The maximum activity was observed in compound bearing R=p-methylphenyl,
o,p-difluorophenyl substituents against B.coccus. The significant activity was observed
in compounds bearing R= o,p-dichlorophenyl, o,p-difluorophenyl against S.aureus.
In case of  Aerogenes all the  compounds were least active, while the compounds
bearing R= p-methyl phenyl, p-nitrophenyl displayed better activity. The compounds
having R= o,p-dinitrophenyl, p-nitrophenyl have shown remarkable activity against
P.aeruginosa.
ANTIFUNGAL  ACTIVITY
All the compounds exhibited mild activity against A. niger  except compounds
having R=o,p-difluorophenyl, p-methylphenyl and p-nitrophenyl showed highest activity
against  A. niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drugs like Griseofulvin.
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Pyrazolines are endowed with multipurpose biological activities. Looking at their
versatile therapeutic importance and with an aim to getting better drug, it was considered
worthwhile to synthesize some new pyrazole of  Type (V).  The preparation of 5-Aryl-
3-isopropyl-4-[N-phenyl-aminocarbonyl]-4,5-dihydro-1H-pyrazoles have been under
taken by cyclocondensation of  3-Aryl-2-isobutanoyl-N-phenyl-acrylamide with
hydrazine hydrate.
SECTION - II
NH
N
CH3
CH3
O
NH
H
H
R
R = ArylType (V)
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-ARYL-3-ISOPROPYL-
4-[N-PHENYL-AMINOCARBONYL]-4,5-DIHYDRO-1H-PYRAZOLES.
105
CH3
CH3
O
OMe
O
NH2
+
CH3
CH3
O
O
NH
O
R
+
Toluene
CH3
CH3
O
O
NH
R
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+
NH2
NH2
CH3
CH3 N
O
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R
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H H
R= Aryl
Reaction Scheme
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IR SPECTRAL STUDIES OF 3-ISOPROPYL-5-PHENYL-4-[N-PHENYL-AMINOCARBONYL]-4,5-
DIHYDRO-1H-PYRAZOLE.
Alkane C – H str.(asym.) 2968.2 2975-2950 108
–CH3 C – H str. (sym.) 2884.8 2880-2860 "
C – H def. (asym.) 1448.4 1470-1435 "
–C (CH3)2 C – H def. 1387.8 1390-1360 "
Aromatic =C – H str. 3036.1 3090-3030 "
C = C str 1602.7 1612-1600 "
C – H i.p. (def) 1251.7 1269-1247 "
1176.5 1181-1171 "
C – H o.o.p. (def) 818.7 832-802 "
Pyrazoline C = N str. 1544.8 1580-1520 109-110
C – N str. 1271.7 1300-1200 "
N – H str. 3332.7 3360-3320 "
Carboxamide C =O 1654.8 1680-1630 "
N – H str. 3296.1 3380-3150 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
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Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal
No.
Multiplicity J. value
in Hz
Signal Position
( δ ppm)
Relative No.
of Protons
1. 1.06-1.10 d d 6H – CH–(CH3)2
3. 2.42-2.50 m 1H – (CH3)2–CH
4. 4.07-4.15 d 1H J=5.2 pyrz–H
5. 4.96-5.05 d 1H J=4.8 pyrz–H
6. 7.03-7.61 Overlapped 10H – Ar-H
7. 10.27 s 1H – N–H
Inference
NMR SPECTRAL STUDIES OF 3-ISOPROPYL-5-PHENYL-4-[N-PHENYL-AMINOCARBONYL]-
4,5-DIHYDRO-1H-PYRAZOLE.
NH
N
CH3
CH3
O
NH
HH
3
108
M
A
SS
  S
PE
C
T
R
A
L
 S
T
U
D
IE
S 
O
F 
3-
IS
O
PR
O
PY
L
-5
-P
H
E
N
Y
L
-4
-[
N
-P
H
E
N
Y
L
-A
M
IN
O
C
A
R
B
O
N
Y
L
]-
4,
5-
D
IH
Y
D
R
O
-1
H
-P
Y
R
A
Z
O
L
E
.
N
H
N
C
H
3
C
H
3
O
N
H M
.W
 =
 3
07
109
m
/z
 =
 2
13
C
H
4
N
N
C
H
2N
H
O
C
+
N
N
O
N
H C
H
2
C
H
2 m
/z
 =
 1
87
N N
O
+
N
H
2
C
H
2
C
H
3 m
/z
 =
 1
71
N
H
m
/z
 =
 9
3
N
H
N
C
H
3
C
H
3
O
N
H
m
/z
 =
 3
07
C
H
+
m
/z
 =
 6
5
C+
m/z = 77-HCN
N
H
O N
H
m
/z
 =
 2
38
N
C
H
3
C
H
3
m
/z
 =
 1
46
N
H
O
+
N
H
2
N
m
/z
 =
 1
03
N
C
H
3
C
H
3
m
/z
 =
 6
9
N
H
C
H
+
m
/z
 =
 1
18
C
O
110
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-ARYL-3-ISOPROPYL-
4-[N-PHENYL-AMINOCARBONYL]-4,5-DIHYDRO-1H-PYRAZOLES.
(A) Synthesis of 4-Methyl-3-oxo-N-phenyl-pentanamide :
           Take the mixture of Methyl-4-methyl-3-oxo-pentanoate (1.44 gm, 0.01 mol)
and aniline (0.93 gm, 0.01 mol) in toluene, containing few drops of ethylene diamine.
The solution  was refluxed for 12 hrs. collect methanol using dean & stark. The resulting
reaction mass was washed with dilute HCl and finaly with water. Separated toluene was
layer was distilled out under vacuum. Yield 71%, m. p. 32oC, Anal.Calcd. for
C12H15NO2 Calcd: C, 70.22; H, 7.37; N, 6.82%, Found:  C, 70.71; H, 7.36; N,
6.81%.
(B) Synthesis of 2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide:
The mixture of  toluene, 4-Methyl-3-oxo-N-phenyl-pentanamide(2.05 gm, 0.01
mol), benzaldehyde (1.06 gm, 0.01 mol), morpholine and acetic acid was heated to the
reflux temperature for 14-16 hrs. Water was removed from the reaction mixture by
Dean and Stark. The mixture was cooled at room temperature. Washed  the reaction
mass with sodiumbisulphite solution and finally washed with distilled water. Distilled out
solvent and  collect the product, purified in hexane. Yield 80%, MP. 144oC, Anal. Calcd.
for C19H18NO2  Calcd: C, 77.79; H, 6.53; N, 4.77%, Found: C, 77.07; H, 6.11; N,
4.09%.
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(C) Synthesis of  3-Isopropyl-5-phenyl-4-[N-phenyl-aminocarbonyl]-4,5-
dihydro-1H-pyrazole :
A mixture of  2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide(2.93gm 0.01mol)
and hydrazine hydrate (0.5gm, 0.01 mol) in methanol  was refluxed for 4 hrs. Cool and
pour the reaction mixture into the crushed ice, filter the material, dry it and purified in
isopropyl alcohol. Yield 56% M.P.. 169-171oC Anal.Calcd. for C19H21N3O  Calcd: C,
74.24; H, 6.89; N, 13.67 %, Found: C, 74.21; H, 6.88; N, 13.64%.
Similarly, other 5-Aryl-3-isopropyl-4-[N-phenyl-aminocarbonyl]-4,5-dihydro-
1H-pyrazoles were prepared. The physical data are recorded in Table No.5.
(D) Biological evaluation of   5-Aryl-3-isopropyl-4-[N-phenyl-aminocarbonyl]-
4,5-dihydro-1H-pyrazoles :
Antimicrobial activity was carried out as described in Chapter-1, Section-I(D),
Page No. 43.  The zones of inhibition of the test solutions are recorded in Graphical
Chart No. 5.
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type (V)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=p-fluoro
phenyl, m-nitrophenyl, p-nitrophenyl substituents against B.coccus. The significant activity
was observed in compounds bearing R= o,p-dimethoxyphenyl, p-methoxyphenyl, m-
phenoxyphenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R=
o-chlorophenyl, p-chlorophenyl against Aerogenes. In the case of P.aeruginosa all the
compounds were least active except R= o-chlorophenyl, p-hydroxy-m-methoxyphenyl,
p-methoxyphenyl.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
Compound having R=o-hydroxyphenyl, p-methoxy phenyl  have shown better activity
against A. niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like  Griseofulvin.
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SECTION - III
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ACETYL-5-ARYL-3-ISO-
PROPYL-4-[N-PHENYL-AMINOCARBONYL]-4,5-DIHYDRO-1H-PYRAZOLES.
The broad spectrums of pharmacological properties have been demonstrated by the
pyrazole nucleus. Inspired by these facts, novel acetyl pyrazoline derivatives of  Type-
(VI) has been undertaken. The synthesis was carried out by the cyclocondensation of
3-Aryl-2-isobutanoyl-N-phenyl-acrylamide and hydrazine hydrate in glacial acetic acid
shown as under.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
Type (VI) R=Aryl
N
N
CH3
CH3
O
NH
H
H
R
O
CH3
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CH3
CH3
O
OMe
O
NH2
+
CH3
CH3
O
O
NH
O
R
+
Toluene
CH3
CH3
O
O
NH
R
Toluenemorpholine/acetic acid
+
NH2
NH2
gla acetic acid
CH3
CH3 N
O
NH
R
N
H H O
CH3
R = Aryl
Reaction Scheme
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IR SPECTRAL STUDIES OF 1-ACETYL-3-ISOPROPYL-5-PHENYL-4-[N-PHENYL-
AMINOCARBONYL]-4,5-DIHYDRO-1H-PYRAZOLE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2971.0 2975-2950 108
–CH3 C – H str. (sym.) 2887.7 2880-2860 "
C – H def. (asym.) 1440.1 1470-1435 "
–C (CH3)2 C – H def. 1380.8 1390-1360 "
Aromatic =C – H str. 3087.7 3090-3030 "
C = C str 1606.1 1612-1600 "
C – H i.p. (def) 1259.2 1269-1247 "
1170.1 1181-1171 "
C – H o.o.p. (def) 839.7 832-802 "
Pyrazoline C = N str. 1549.5 1580-1520 109-110
C – N str. 1240.1 1300-1200 "
Carboxamide C =O 1635.5 1680-1630 "
N – H str. 3274.2 3380-3150 "
Carbonyl N-C=O 1690.6 1760-1650 "
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Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal
No.
Multiplicity J. value
in Hz
Signal Position
(δ ppm)
Relative No.
of Protons
1. 1.18-1.12 d d 6H – CH–(CH3)2
2. 2.22 s 3H – CO–CH3
3. 2.50-2.66 m 1H – (CH3)2–CH
4. 3.99-4.01 d 1H J=4.2 pyrz–H
5. 5.44-5.46 d 1H J=4.4 pyrz–H
6. 7.10-7.61 Overlapped 10H – Ar-H
7. 10.42 s 1H – N–H
Inference
NMR SPECTRAL STUDIES OF 1-ACETYL-3-ISOPROPYL-5-PHENYL-4-[N-PHENYL-
AMINOCARBONYL]-4,5-DIHYDRO-1H-PYRAZOLE.
N
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ACETYL-5-ARYL-3-ISO-
P R O P Y L - 4 - [ N - P H E N Y L - A M I N O C A R B O N Y L ] - 4 , 5 - D I H Y D R O - 1 H -
PYRAZOLES.
(A) Synthesis of 4-Methyl-3-oxo-N-phenyl-pentanamide :
           See  Chapter-2, Section-II (A), Page No.110.
(B) Synthesis of 2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide :
See Chapter-2, Section-II (B), Page No. 110.
(C) Synthesis of 1-Acetyl-3-isopropyl-5-phenyl-4-[N-phenyl-aminocarbonyl]-
4,5-dihydro-1H-pyrazole:
A mixture of  2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide(2.93gm 0.01mol)
in glacial acetic acid  (25 ml) and hydrazine hydrate (0.5gm, 0.01 mol) was heated on
water bath at 70oC for 8 hrs.Cool the reaction mixture and poured into the crushed ice.
Filtered the product and washed with water, dried and recrystalized in isopropyl alcohol.
Yield 41% M.P.. 220-222oC  Anal.Calcd. for C21H23N3O2  Calcd: C, 72.18; H, 6.63;
N, 12.03 %, Found: C, 72.16; H, 6.61; N, 12.00%.
Similarly, other 1-Acetyl-5-aryl-3-isopropyl-4-[N-phenyl-aminocarbonyl]-4,5-
dihydro-1H-pyrazoles were prepared. The physical data are recorded in Table No.6.
(D) Biological evaluation of   1-Acetyl-5-aryl-3-isopropyl-4-[N-phenyl-
aminocarbonyl]-4,5-dihydro-1H-pyrazoles :
Antimicrobial activity was carried out as described in Chapter-1, Section-I(D),
Page No. 43. The zones of inhibition of the test solutions are recorded in Graphical
Chart No.6.
EXPERIMENTAL
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type
(VI) were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
In Gram positive bacterial strains the compounds bearing R=p-chlorophenyl, o-
chlorophenyl substituents  have displayed good activity against B.coccus. The compounds
bearing R= p-methoxy phenyl, p-methylphenyl have shown considerable activity against
S.aureus.
In case of  Gram negative bacterial strains,  the significant activity was display by
the compound bearing R= p-methoxy phenyl, m-nitrophenyl against Aerogenes. While
the compounds bearing R= p-methylphenyl, m-nitrophenyl are active against
P.aeruginosa.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However  the compounds having R=p-nitrophenyl, p-methoxyphenyl and m-phenoxy
phenyl are highly active against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug Griseofulvin.
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 INTRODUCTION  :
1,4-Dihydropyridine is the significant subclass of pyridines, the best known het-
erocyclic compounds which are associated with  number of pharmacological activities.
The credit for the discovery of 1,4-dihydropyridine goes to Hantzsch in 18821,2 pub-
lished the synthesis in its simplest form involves heating an aldehyde, 1,3-diketone and
ammonia.
The DHP nucleus is common to numerous bioactive compounds  which passes
various type of activity like vasodilator, antihypertensive, bronchodilator, antiatheroscle-
rotic, hepatoprotective, antitumor, antimutagenic, geroprotective and antidiabetic.3-8
Many  drug molecules bearing 1,4-dihydropyridine nucleus  are  specifically re-
lated with calcium channel antagonism9 and antihypertensive.10  Earlier it was believed
that, the dihydropyridine is useful only as calcium channel antagonist, but  later on due
to QSAR study and X-ray crystallography study of new synthetic dihydropyridine mol-
ecules indicates that their therapeutic activities may be broaden to ionotrophy to secre-
tary stimulations also. Currently these drugs are target for angina, hypertension, hyper-
trophic cardiomyopathy, cerebral vasospasm and other smooth muscle disorders.
From  study of DHP compounds,  it  is found that both the ester groups present
at 3 and 5 position play an important role in cardiovascular activity, removal of these
groups may led to reduction of the activity.11   This   conclusion has open up new  scope
for structural modifications at these positions. Very wide range of literature regarding
the structure, synthesis, stereochemistry and  hydrogen transfer mechanism of dihydro-
pyridine is available.12-17  More than 10,000 articles,  publications  &  patents are pub-
lished on the  1,4-DHPs indicate that the interest on DHP is increased world wide.
The key characteristic of calcium channel blockers is their inhibition of entry of
calcium ions via a subset of channels, there by leading to impairment of
contraction. There are three main groups of calcium channel blockers, i.e. dihydropy-
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ridines, phenylalkylamines and benzothiazepines. Typical examples of which are
nifedipine, verapamil and diltiazem respectively.18,19 Each has a specific receptor on the
calcium channel and a different profile of pharmacological activity. Dihydropyridines
have a less negative inotropic effect than phenylalkylamines and benzothiazepines.
SYNTHETIC ASPECT :
In 1882,  1,4-dihydropyridine was introduced by Hantzsch1,2  in a single step
preparation. The work was limited to symmetric diester at   position C3 and C5 involving
the condensation of an aldehyde, ammonia and acetoacetic ester. After  that the 1,3-
dicarbonyl compound was utilized by Beyer  and later by Knoevenagel20 to modify the
preparation of unsymmetrical 1,4 dihydropyridine by condensation of an alkylidene or
arylidene 1,3-dicarbonyl compound with β-amino-α,β- unsaturated carbonyl compound
for getting pure product avoiding side products.21-24
1,4-Dihydropyridines not only are intermediates for the synthesis of pyridines,
but also are themselves an important class of N-heterocycles,25,26 an example is the
coenzyme NADH. Studies on the function of NADH led to increased interest in the
synthesis of dihydropyridines as model compounds. Aryl-substituted dihydropyridines
have been shown to be physiologically active as calcium antagonists. Some derivatives
have found application in the therapy of high blood pressure and angina pectoris.27 For
that reason the synthesis of 1,4-dihydropyridines has been the subject of intensive research
and industrial use. The Hantzsch synthesis has thus become an important reaction.
Different synthetic methods for the synthesis of 1,4-dihydropyridine are as follows.
(1) By the condensation of aromatic or aliphatic aldehydes with acetoacetate and
aromatic or aliphatic amine in presence of pyridine.28,29
(2) By the condensation of aliphatic or aromatic aldehydes with 3-aminocrotonate
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(6). Alexander Kornienko et al.42 have synthesized dihydropyridine derivatives by
the cyclocondensation of aldehyde and malononitrile and thioderiva
tives in the presence of triethyl amine.
O
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R1 SH
N
H
NH2 S
CNNC
R
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Et3N
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Reflux
+ +
and 1,3 -diketone.30-36
(3) By the condensation of arylidene with 3-aminocrotonate.37
(4) By the condensation of aliphatic or aromatic aldehydes with various 1,3-dike
tones in presence of ammonia or ammonium carbonate.38-40
(5) Shengkai Ko et al.41  have synthesized 1,4-dihydropyridine  by one pot reac-
tion, catalyzed by iodine at room temperature.
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REACTION MECHANISM OF 1,4-DIHYDROPYRIDINES.
The initial step of the Hantzsch synthesis is likely to be a Knoevenagel
condensation reaction of aldehyde (II) and β-ketoester (I) to give the α,β-unsaturated
ketoester (III). The enamine is formed by the condensation of the β-ketoester (I) and
ammonia. The ring synthesis then proceeds in subsequent steps by condensation of the
unsaturated ketoester (III) and enamine (IV) to yield a 1,4-dihydropyridine (V).43-49
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THERAPEUTIC IMPORTANCE.
1,4-Dihydropyridines are now established as heterocycles having tremendous
applications and still further scope for its pronounced drug  activity like calcium channel
antagonism and antihypertensive action. Many other cardiovascular activities are asso-
ciated with such compounds and they can be presented in the structure  as 2,6-dim-
ethyl-3,5-diacetyl or dicarboxylate or dicarbamoyl or many other homoaryl or heteroaryl
or carbon chain having C2 to C8   at 4-position.
The credit for the discovery of 1,4-dihydropyridine in a single step goes to Hantzsch
in 1882. Till the great block buster cardiovascular drug Nifedipine50  launched in the
market, limited  work  had been done in the area of unsymmetric diesters at position 3
and 5. Since then tremendous study have been carried out on new synthesis & pharma-
cological activity of DHP. Some drugs currently used in market are Nimodipine51,
Nicardipine52,53, Isradipine54, Nitrendipine55, Flordipine56,Benidipine57,Felodipine58,
Riodipine59, Nilvodipine60, Amlodipine61, Darodipine62, Taludipine63, Lecidipine64,
Sagandipine65, Lemildipine66,Furnidipine67, Azelnidipine68, Barnidipine69, Efonidipine70,
Iganidipine71, Manidipine.72Some of their compounds are characterized by longer bio-
activity of greater tissue selectivity 1,4-dihydropyridine derivatives are associated with
diverse biological activities viz.1,4- DHPs possess different pharmacological activities
such as.
1. Myocardial infarction.73-75
2. Stable76,77 and unstable angina.78,79
3. Vasodilator.80
4. Coronary vasodilator and cardiopathic.81
5. Antiarrhythmic.82
6. Antiulcer.83
7. Antiallergic.83
8. Antiinflammatory.84
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9. Subarachnoid hemorrhage.85,86
10. Ischemic brain damage.87
11. Atherosclerosis.88
12. Heart failure.89
13. Calcium channel antagonism.90
14. Antitumor. 91
15. Antimayocardiac ischemic.92
16. PAF antagonist.93
17. Adenosine A3 receptor antagonist.
94
18. MDR reversal activity.95,96
19. Antitubercular agents.97
Carlos et,al.98  reported 1,4-DHPs derivatives with a 1,2-benzothiazol-3-one 1-
sulphoxide group (VI), linked through an alkylene bridge to the C3 carboxylate of the
DHP ring, with both vasoconstricting and vasorelaxant properties were obtained. In
blocking Ca+2 evoked contractions of K+depolarized rabbit. Many compounds were 10
times more potent than nifedipine.
O
N
H
CH3 CH3
OH OH
OO
S
N
O
O
O
CH3
(VI)
139
Hernandez-Gallegos and coworkers99  have  synthesized new 1,4-dihydropyridines
(VII) and evaluated their relaxant ability (rat aorta), antihypertensive activity in sponta-
neously hypertensive rats and their microsomal oxidation rate   (MOR) was determined.
N
H
CH3 CH3
COO-R2R1COO
(VII)
A new positive inotropic agent with high cardioselectivity, found in Bay-y-5959100
(VIII) with calcium channel modulating activity and devoid of vasoconstricting effects
in dogs and currently under going phase II trials for the treatment of congestive heart
failure.
N
H
MeNH2
O
O
CN
N
CH3
CH3
Bay-y-5959 
Cozzi et al.101   studied anticancer activity especially as an aromatase inhibitory
activity of dicyano and cyanoester derivatives of 1,4-DHP containing an imidazol-1-yl
or 1,2,4-triazol-1-yl ring (IX) at C4 position of phenyl ring. Aromatase inhibitory activ-
ity recorded in vitro.
(VIII)
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Pharmacological screening of the new 1,4-dihydropyridines were  carried out
for CNS depressant (anticonvulsant and analgesic) and cardiovascular(inotropic and
blood pressure) activities by standard  methods.  Pommier Z. and co-workers102   have
identified 3,5-dicarbamoyl derivative NSC-372643  (X) as an anti-HIV agent.
(IX)
N
H
MeMe
NO2
N
H
OO
N
H
OH
OH
OH
OH
NSC - 372643
Uneyama and coworkers103    found activity of (XI) in vitro inhibited N-Type and
L-Type calcium channel in rat  and it shows in a sympathetic ganglion cell.
(X)
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Kilcigil and coworkers104 synthesized new type of symmetrical dicarbamoyl 1,4-
dihydropyridine (XII) with some flavone derivatives at C4 position of DHP ring by re-
acting 6-formylflavones with acetoacetanilide. Their aim was to investigate the calcium
antagonistic activity on this skeletal changes. Few  newly synthesized compounds showed
good calcium antagonistic activity  with  nifedipine as the reference compound.
N
H
CH3CH3
CO
NH
CO
NH
O
O
Shah A.et al.105  have synthesized 4-Phenyl-3,5-diacetyl-1,4-dihydropyridines
(AcDHPs) (XIII) and 4-Phenyl-3,5-dibenzoyl-1,4-dihydropyridines (BzDHPs) (XIV)
substituted at the phenyl ring and compared for their cytotoxic activity and multidrug
resistance (MDR) reversing activity in in vitro assay systems.
(XII)
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R= CF3,R= CF3, H, NO2, Cl etc.... H,
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Shah A.et al 106  synthesized  4-Substituted phenyl-2,6-dimethyl-3,5-bis-(N-sub-
stituted phenyl)- carbamoyl-1,4-dihydropyridine (XV) and studied their 2D QSAR  as
well as  antitubercular activity against M.tuberculosis H37Rv , among them some de-
rivatives show >90% inhibition comparable to rifampicin.
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R
R= 3-OC6H5,Cl NO2 Br .... R1= NO2, Cl, Br ....
(XIII) (XIV)
(XV)
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Andreas Hilgeroth and co-workers107 have synthesized 1,4-dihydropyridine
derivatives as competitive HIV-1 protease inhibitors.
Mosami Kawase  and co-workers108 have documented dihydropyridine derivative
(XVI) as MDR reversal in tumor cells.
N
H
CH3CH3
COPhPhOC
Cl
(XVI)
Sing Yuen Sit et al.109  have synthesized novel dihydropyridine derivatives (XVII)
as NPY antagonists.
N
H
CH3CH3
COOCH3H3COOC
NH NH
Z
N
Y R
(XVII)
A. Zarghi et al.110 have synthesized pyridine derivatives and reported their cal-
cium antagonist activity. Adam Daich et al.111 prepared 1,4-dihydropyridine (XVIII) of
calcium antagonist. Margarita Suarez et al.112 prepared calcium   antagonist  modulators
1,4-dihydropyridine (XIX).
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(XVIII)
Saponara and group113 have investigated the effects of AcDHPs and BzDHPs
on vascular functions in vitro, by comparing their mechanical and electrophysiological
actions, as well as to quantify their MDR reversal properties.
(XX)
Sonja114 and group have synthesized a new series of calcium channel agonists
(XX) structurally related to Bay K8644. The racemic mixtures were studied for their
action on L-type Ca2+ channels expressed in cultured rat insulinoma  cells. All the prod-
ucts proved to be potent calcium channel agonists.
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Carlos Velazquez and Edward E. Knaus115   have reported pyridine derivatives
(XXI) as potential treatment of congestive heart failure.
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O O CH3
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O
(XXI)
1,4-Dihydropyridine containing 3-Methoxy-flavone moiety (XXII) have synthe-
sized by Roberta Budriesi et al.116 and reported as calcium channel modulators.
Anil K. Chhillar et al.117 have synthesized dihydropyridine derivative (XXIII)
and reported their antimicrobial and antifungal activity.
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In light of wide varieties of biological activities exhibited by dihydropyridines, it
appeared of interest to synthesize dihydropyridine derivatives, in order to achieving
compounds having better therapeutic activity described as under.
SECTION-I  : SYTHESIS AND BIOLOGICAL EVALUATION OF 4-
ARYL-2 ,6-DIISOPROPYL-3,5-BIS[N-PHENYL-
AMINOCARBONYL]-1,4-DIHYDROPYRIDINES.
SECTION-II  : SYTHESIS AND BIOLOGICAL EVALUATION OF
METHYL-4-ARYL-6-ISOPROPYL-2-METHYL-5-[N-
PHENYL-AMINOCARBONYL]-1,4-DIHYDROPYRIDINE-
3-CARBOXYLATES.
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SECTION - I
SYTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-2,6-DIISOPROPYL-
3,5-BIS[N-PHENYL- AMINOCARBONYL]-1,4-DIHYDROPYRIDINES.
1,4-Dihydropyridine derivatives have considerable attention in view of their
potential pharmacological properties such as antimicrobial, anticonvulsant, anticancer,
etc. Lead by these considerations, the synthesis of 1,4-dihydropyridine derivatives of
Type-(VII) has been undertaken. The synthesis was carried out by the condensation of
3-Aryl-2-isobutanoyl-N-phenyl-acrylamide and 4-Methyl-3-oxo-N-phenyl-pentanamide
and ammonia shown as under.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
N
H
CH3
CH3
O
NH
R
CH3
CH3
NH
O
Type (VII) R=Aryl
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Reaction Scheme
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IR SPECTRAL STUDIES OF 2,6-DIISOPROPYL-4-PHENYL-3,5-BIS[N-PHENYL-
AMINOCARBONYL]-1,4-DIHYDROPYRIDINE.
 Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2951.0 2975-2950 A
–CH3 C – H str. (sym.) 2863.5 2880-2860 "
C – H def. (asym.) 1435.9 1470-1435 "
–C (CH3)2 C – H def. 1384.8 1390-1360 "
Aromatic =C – H str. 3068.4 3090-3030 "
C = C str 1606.2 1612-1600 "
1579.6 1585-1573 "
C – H i.p. (def) 1258.4 1269-1247 "
1172.7 1181-1171 "
C – H o.o.p. (def) 807.5 832-802 "
Pyridine C = C str. 1579.6 1580-1520 109-110
C – N 1295.9 1300-1200 "
N – H str. 3428.2 3440-3400 "
C – N str. 1245.9 1305-1200 "
Carboxamide C =O 1685.7 1680-1630 "
N – H str. 3256.6 3380-3150 "
N
H
CH3
CH3 CH3
CH3
NH
OO
NH
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NMR SPECTRAL STUDIES OF 2,6-DIISOPROPYL-4-PHENYL-3,5-BIS[N-PHENYL-
AMINOCARBONYL]-1,4-DIHYDROPYRIDINE.
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons
1. 1.20-1.26 d d 6H CH–(CH3)2
2. 3.503.58 m 1H (CH3)2–CH
3. 5.49 s 1H pyr–H
4. 7.16-7.58 Overlapped 15H Ar-H
5. 7.65 s 1H N–H
6. 8.72 s 2H N–H
Inference
N
H
CH3
CH3 CH3
CH3
NH
OO
NH
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EXPERIMENTAL
SYTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-2,6-DIISOPROPYL-
3,5-BIS[N-PHENYL-AMINOCARBONYL]-1,4-DIHYDROPYRIDINES.
(A) Synthesis of 4-Methyl-3-oxo-N-phenyl-pentanamide :
           See  Chapter-2, Section-II (A), Page No. 110.
(B) Synthesis of 2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide :
See Chapter-2, Section-II (B), Page No.110.
(C) S y n t h e s i s  o f  2 , 6 - D i i s o p r o p y l - 4 - p h e n y l - 3 , 5 - bis[N-phenyl-
aminocarbonyl] -1,4-dihydropyridine:
To a  mixture of  2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide(2.93gm 0.01mol)
and 4-Methyl-3-oxo-N-phenylpentanamide (2.05gm, 0.01mol) in methanol, add liq
ammonia and reflux on water bath for 12 hrs. Cool the reaction mixture at room temprature
and stand by for a day. The resulting solid mass was filtered and washed with methanol.
The product was recrystalized into DMF and methanol. Yield 56% m.p. 210-212oC
Anal.Calcd. for C31H33N3O2 Calcd: C, 77.63; H, 6.94; N, 8.76 %, Found: C, 77.56;
H, 6.88; N, 8.70%.
Similarly, other 4-Aryl-2,6-diisopropyl-3,5-bis[N-phenyl-aminocarbonyl]-1,4-
dihydropyridines were prepared. The physical data are recorded in Table No.7.
(D) Biological evaluation of 4-Aryl-2,6-diisopropyl-3,5-bis[N-phenyl-
aminocarbonyl]-1,4-dihydropyridines:
Antimicrobial activity was carried out as described in Chapter-1, Section-I(D),
Page No. 43. The zones of inhibition of the test solutions are recorded in Graphical
Chart No. 7.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of Type
(VII ) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However the maximum activity was observed in compounds bearing R=p-
fluorophenyl, p-nitrophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R=p-nitrophenyl, p-methoxy phenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-methoxy
phenyl, p-nitro phenyl against Aerogenes. In the case of P.aeruginosa all the compounds
were least active except R= o-chlorophenyl, p-methyl phenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
All the compounds are active against A. niger.  While compounds having R=p-chloro
phenyl, p-methyl phenyl and 3-4-dimethoxy phenyl  shown significant activity.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION-II
SYTHESIS AND BIOLOGICAL EVALUATION OF METHYL-4-ARYL-6-
ISOPROPYL-2-METHYL-5-[N-PHENYL-AMINOCARBONYL]-1,4-DIHYDRO-
PYRIDINE-3-CARBOXYLATES.
It is well known that 1,4-dihydropyridines and related compounds exhibite a
wide range of biological activities. Looking to the interesting therapeutic activity,  we
have prepared compounds of Type (VIII) which have been synthesized by the
condensation of  3-Aryl-2-isobutanoyl-N-phenyl-acrylamide and Methyl-3-amino-
crotonate.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
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N
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O
NH
IR SPECTRAL STUDIES OF METHYL-6-ISOPROPYL-2-METHYL-4-PHENYL-5-[N-PHENYL-
AMINOCARBONYL]-1,4-DIHYDROPYRIDINE-3-CARBOXYLATE.
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2945.1 2975-2950 A
–CH3 C – H str. (sym.) 2855.7 2880-2860 "
C – H def. (asym.) 1429.2 1470-1435 "
–C (CH3)2 C – H def. 1383.8 1390-1360 "
Aromatic =C – H str. 3030.3 3090-3030 "
C = C str 1603.6 1612-1600 "
C – H i.p. (def) 1185.2 1181-1171 "
1120.6 1124-1110 "
1020.3 1018-1008 "
C – H o.o.p. (def) 811.0 832-802 "
Pyridine C = C str. 1519.5 1580-1520 "
C – N 1218.0 1300-1200 "
N – H str. 3314.4 3440-3400 "
Carboxamide C =O 1667.3 1680-1630 "
N – H str. 3257.9 3380-3150 "
Ester C =O  str. 1703.0 1730-1700 "
C– O str. 1292.2 1300-1250 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
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NMR SPECTRAL STUDIES OF METHYL-6-ISOPROPYL-2-METHYL-4-PHENYL-5-[N-PHENYL-
AMINOCARBONYL]-1,4-DIHYDROPYRIDINE-3-CARBOXYLATE.
N
H
CH3
CH3
O
NH
CH3
COOMe
Ha
1. 1.26-1.21 d,d 6H CH–(CH3)2
2. 2.33 s 3H C-CH3
3. 3.66 s 3H COO-CH
3
4. 3.79-3.86 m 1H (CH3)2–CH
5. 4.80 s 1H Pry–CHa
6. 6.99-7.43 Overlapped 10H Ar-H
7. 7.00 s 1H N–H
8. 7.08 s 1H N–H
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons Inference
Internal Standard : TMS; Solvent : CDCl3    : Instrument : BRUKER Spectrometer (400 MHz)
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SYTHESIS AND BIOLOGICAL EVALUATION OF METHYL-4-ARYL-6-
ISOPROPYL-2-METHYL-5-[N-PHENYL-AMINOCARBONYL]-1,4-DIHYDRO-
PYRIDINE-3-CARBOXYLATES.
(A) Synthesis of 4-Methyl-3-oxo-N-phenylpentanamide :
           See  Chapter-2, Section-II (A), Page No.110.
(B) Synthesis of 2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide :
See Chapter-2, Section-II (B), Page No.110.
(C) Synthesis of Methyl-6-isopropyl-2-methyl-4-phenyl-5-[N-phenyl-
aminocarbonyl]-1,4-dihydropyridine-3-carboxylate :
A mixture of  2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide(2.93gm 0.01mol)
and Methyl-3-aminocrotonate (1.15gm,0.01mol) in methanol was refluxed  in water
bath for 18hrs. Cool down reaction mixture at room tempreture and stand by 24 hrs.
The resulting solid mass was filtered and washed with methanol. Recrystalized  the product
in methanol.Yield 50% m.p. 191-193oC Anal.Calcd. for C24H26N2O3 Calcd: C, 73.82;
H, 6.71; N, 7.17 %, Found:  C, 73.78; H, 6.76; N, 7.16 %.
Similar ly,  other  Methyl-4-aryl-6- isopropyl-2-methyl-5-[N-phenyl-
aminocarbonyl]-1,4-dihydropyridine-3-carboxylates were prepared. The physical data
are recorded in Table No. 8.
(D) Biological evaluation of Methyl-4-aryl-6-isopropyl-2-methyl-5-[N-phenyl-
aminocarbonyl]-1,4-dihydropyridine-3-carboxylates:
Antimicrobial testing was carried out as described in Chapter-1, Section-I(D),
page No.43.  The zones of inhibition of test solutions are recorded in Graphical Chart
No. 8.
EXPERIMENTAL
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type
(VIII) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However the maximum activity was observed in compounds bearing R=p-
fluorophenyl,m-nitrophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R=m-nitrophenyl, p-fluorophenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R=o-hydroxy
phenyl, m-phenoxyphenyl against Aerogenes. In case of P.aeruginosa all the compounds
were least active except R= p-chlorophenyl, m-phenoxy phenyl.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
All the compounds exhibited mild activity against A. niger.  While compounds having
R=m-phenoxy phenyl, p-methyl phenyl and phenyl shown significant activity.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug Griseofulvin.
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INTRODUCTION
Pyridine the simplest and perhaps is the best-known heterocyclic compound.
The credit for the discovery of pyridine goes to Anderson who first obtained it from
bone oil. Pyridine ring system is highly distributed in nature as pyridine derivatives and
in many important alkaloids.
The pyridine nucleolus was found in a large number of commonly used drugs,
which have diverse pharmacological activities. Interest in the synthesis of pyridine
containing compounds has increased in recent years because of their biological and
pharmacological activities.
Pyridine is the parent compound of the series of compounds that is important in
pharmaceutical, agriculture and industrial chemistry. Among a wide range of pyridines,
3-cyanopyridines acquired a special attention due to their wide range of therapeutic
activities.
SYNTHETIC ASPECTS
Most of these derivatives are prepared by manipulation of pyridine and its simple
homologues in a manner similar to chemistry of the benzenoid chemistry. However the
simple pyridine compounds are prepared by the Cyclization of aliphatic raw materials.
Preparation of 3-cyanopyridines is available in the literature1-5 with different methods.
1. Samour and co-workers6 have prepared substituted cyanopyridines by the
condensation of chalcones with malononitrile in presence of ammonium acetate.
R
O
R1
CH2(CN)2
CH3COONH4
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MECHANISM
The reaction proceeds through conjugate addition of active methylene compounds
to the α,β-unsaturated system as shown below.
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CN NaOCH3
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2. Feng Shi and co-workers7  have prepared 2-amino-3-cyanopyridine derivative
by the reaction of aromatic aldehyde, ketone, malononitrile and ammonium
acetate under microwave irradiation without solvent.
3. Dao-Lin & Kimiaki 8 have prepared 2-methoxy-3-cyanopyridine derivatives by
the condensation of α,β-unsaturated ketones with malononitrile in sodium
methoxide
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THERAPEUTIC IMPORTANCE :
Pyridine with different functional groups, exhibit wide range of applications in
the field of medicine, agriculture and dyes. Although many substituted pyridine compounds
like other heterocyclic compounds are synthesized with their functional group present
in  cyclic compounds. The availability of 3-cyanopyridines, nicotinamide and nicotinic
acid make possible their use as synthetic intermediates. The extensive use of cyanopyridine
derivatives have been established in medicine due to its antihypertensive, anticholestemic,
antidiabetic, antifungal and antibacterial properties.
1.  Antifungal.9
2.  Antiepileptic.10
3.  Antibacterial.11
4. Anticonvulsant.12
5. Antitubercular.13
6. Analgesic.14
7. Insecticidal.15
8. Antisoriasis.16
9. Antihypertensive.17
Streightoff A.18 and Seydel J.19 have studied the bacteriostatic effect of some
substituted 3-cyanopyridines. J. A. Van Allan et al.20 have prepared fused heterocyclic
3-cyanopyridine.(I)
S N
N
C6H5
NH2
N
 (I)
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Barton et al.21 have reported fungicidal and insecticidal properties of
cyanopyridines.  J. J. Baldwin22-24 have prepared cyanopyridines exhibiting
antihypertensive activity. V. Scott and E. Joseph25,26 have prepared 2-amino-3-
cyanopyridine derivatives which were found to be useful as antipsoriasis. Miertus et
al.27 synthesized 2-formyl 3-cyanopyridine thiosemicarbazone as a carcinostatic agent.
S. S. Verma et al.28 and M. D. Ankhiwala29 have synthesized 2-amino-3-cyano-2,6-
disubstituted pyridines and studied their biological activities. F. Manna et. al.30 have
prepared 3-cyanopyridine derivatives as antiinflammatory, analgesic and antipyretic
agents. Gadaginamath and co-workers31 have synthesized various cyanopyridine
derivatives (II) and documented their biological activities.
NNNH2
NC
H3CO
R
CH3
CH3
O
(II) R = Aryl
The insecticidal activity of cyanopyridines have been screened by Y. Sasaki32
and coworkers. Pankaj Patel & co-workers33 have synthesized cyanopyridines and
evaluated their biological activity. Umed Ten et al.34 have prepared cyanopyridines as
agro fungicides.
The oxide activator bleaching activity of cyanopyridine has been proved by Rees
W.  M.35 Oshida M.36 prepared cyanopyridine derivatives which inhibited cerebral edema
and delayed neuron death. Hence, they are useful as cerebral edema inhibitors or
cerebrovascular disorder remedies. S. Guru et al.37 have synthesized various
cyanopyridine derivatives (III) and documented their multiple biological activities.
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Some other new cyanopyridine derivatives are reported for their cholinesterase
inhibitors,38 antihistaminic and adrenergic,39 herbicidal,40 antiinflammatory41 &
insecticidal42 activities. H. Yoshida et. al.43 have studied the antihistaminic & antiallergic
activity of 3-cyanopyridine derivatives. John A. Tucker et al.44 have synthesized novel
piperazinyl oxazolidinone containing cyanopyridine (IV) as an antibacterial agents.
N
N
N O
O
F
NHAc
N
N
(IV)
El-Nabawia et al.45 have prepared new 2-amino-3-cyano pyridine derivatives
(V) and studied their antimicrobial activity.
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N
N CH3
C CH3
O
R
C
NH2
N
(V)
Abdallah N. et al.46 have synthesized cyanopyridine derivatives which shows
analgesic and antiinflammatory activity. Adriano Atonso et al.47 have found that
cyanopyridines are Farnesyl protein transferase inhibitors.  Aivars Kruaze et. al.48 have
synthesized 3-cyanopyridine derivatives & shown their neurotropic activity. Abu and
co-workers49 have described novel fused cyanopyridines (VI) for the treatment of
systemic fungal infection.
(VI)
N S
N
NH2
CN
NH2
NC
CH3
Rajeev Doshi and co-workers50 have described some novel cyanopyridines as a
new class of potential antitubercular agents.
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N
N
N
Ar
NH2 NH2
ArN N
 (VII)
Edwin B. Villhauer and co-worker53 have synthesized the series of  cyanopyridines
as a DPP-IV inhibitor. One compound  (VIII) is profiled as a potent, selective and short
acting DPP-IV inhibitor that has excellent oral bioavailability and potent antihyperglycemic
activity. S. V. Roman et. al.54 have investigated 2-amino-3-cyanopyridine derivatives
and reported their biological activity.
N NH
NH
O
N
CN
NC
(VIII)
Abd El-Galil and co-workers51 have prepared 3-cyanopyridines (VII) and studied
their pharmacological activity. Hammung E. and Abou and co-workers52 have studied
the anticancer and anti-HIV activity of 3-cyanopyridines.
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Pyachenko U. D. and co-workers56 have shown some cyanopyridines (X) useful
in treatment of retroviral disease. Cyanopyridines have been screened by A. V. Dobaria
et. al.57 and showed their significant biological activity.
(X)
N
CN
NC
NH2
Se
El-Tawell and co-workers55 have described cyanopyridine derivatives (IX) and
showed their significant biological activity.
N
O
NH2NC
(IX)
Hussain et al.58 have synthesized cyanopyridines as antimicrobial agent. Wu
Wenxue et al.59  have synthesized cyanopyridines as histamine H3 antagonists.  Harada
Hironori et al.60 have prepared cyanopyridines and screened for their large conductance
calcium activated potassium channel opener activity. Marco J. L. et al61 have synthesised
cyanopyridines of acetylcholinesterase inhibitors.
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Rosentreter Ulrich et al62 have synthesised a new cyanopyridine (XI) as receptor
agonists in the treatment of cardiac disease, cancer, inflammation and neurodegenerative
disease. Moustafa M. A. et al.63 have prepared cyanopyridine derivatives and evaluated
for their antibacterial activity.
N
CN
CNR2CH2S
NH2
O(CH2)n OR1
(XI)
Fatma Goda & co-workers64 have synthesized cyanopyridines (XII) and studied
their antimicrobial activity.
N
CN
O
Ar
Ar
CH3
(XII)
Ketan Hirpara & co-workers65 have discovered cyanopyridines as antitubercular
agents (XIII). Eduardo H.S. Sousa et al66 have synthesized cyanopyridine derivetives as
an an antituberculosis.
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N
N
S
N
NH2
N
R
(XIII)
Gary T. Wang and co-worker67 have synthesized  2’-trifluoromethylbiphenyl
substituted 2-amino-nicotinonitrile (XIV) as inhibitors of farnesyl transferase.
N
O
N
N
NC
N
R1
R2
F3C
CN
CH3
(XIV)
Henryk foks et al.68 investigated new 3-cyanopyridine derivatives showing an
antibacterial activity. Abdel-Galil E. Amr and Mohamed M. Abdulla
69 
have synthesized
pyridine derivative (XV) fused with steroidal structure. Initially the acute toxicity of the
compounds was essayed via the determination of their LD50.
 (XV)
N
O
CH3
NC
Ar
CH3
CH3
CH3
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In view of therapeutic activities shown by cyanopyridines, it was contemplated
to synthesize some new cyanopyridines in search of agents possessing higher biological
activity  have been described as under.
SECTION-I    : SYTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-
3-CYANO-6-ISOPROPYL-2-METHOXY-5-[N-PHENYL-
AMINOCARBONYL]-PYRIDINES.
SECTION-II    : SYTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-
3-CYANO-2-ETHOXY-6-ISOPROPYL-5-[N-PHENYL-
AMINOCARBONYL]-PYRIDINES.
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SECTION - I
SYTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-3-CYANO-6-
ISOPROPYL-2-METHOXY-5-[N-PHENYL-AMINOCARBONYL]-PYRIDINES.
Pyridine nucleus plays an important role in medicine, agriculture and
industrial chemistry.  In the light of these biological activities and variety of industrial
applications, some new  2-methoxy cyanopyridine derivatives of Type (IX) have been
prepared by the cyclocondensation of 3-Aryl-2-isobutanoyl-N-phenyl-acrylamide with
malononitrile and sodium methoxide.
N
CH3
CH3
O
NH
O
R
CH3
CN
Type (IX) R= Aryl
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
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Reaction Scheme
CH3
CH3
O
OMe
O
NH2
+
CH3
CH3
O
O
NH
O
R
+
Toluene
CH3
CH3
O
O
NH
R
Toluenemorpholine/acetic acid
+
R= Aryl
CN
N
NaOCH3
N
CH3
CH3
O
CN
RO
NH
CH3
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IR SPECTRAL STUDIES OF  4-(p-CHLOROPHEYNYL)-3-CYANO-6-ISOPROPYL-2-METHOXY-
5-[N-PHENYL-AMINOCARBONYL]-PYRIDINE.
Alkane C – H str.(asym.) 2987.1 2975-2950 A
–CH3 C – H str. (sym.) 2871.0 2880-2860 "
C – H def. (asym.) 1434.9 1470-1435 "
–C (CH3)2 C – H def. 1384.8 1390-1360 "
Aromatic =C – H str. 3013.0 3080-3030 "
C = C str 1600.8 1612-1600 "
1584.1 1585-1573 "
C – H i.p. (def) 1271.0 1269-1247 "
1173.4 1181-1171 "
1120.6 1124-1110 "
C – H o.o.p. (def) 802.3 832-802 "
Pyridine C = C str. 1633.6 1680-1580 "
C=N str. 1584.1 1580-1550 "
Carboxamide C =O 1685.7 1680-1630 "
N – H str. 3246.0 3380-3150 "
Nitrile C=N str. 2217.1 2240-2220 "
Chloride C-Cl str 744.5 800-600 "
Ether C-O-C 1251.5 1200-1260 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
N
CH3
CH3
O
NH
O
CH3
CN
Cl
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NMR SPECTRAL STUDIES OF  4-(p-CHLOROPHEYNYL)-3-CYANO-6-ISOPROPYL-2-
METHOXY-5-[N-PHENYL-AMINOCARBONYL]-PYRIDINE.
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal
No.
Multiplicity J. value
in Hz
Signal Position
(δ ppm)
Relative No.
of Protons Inference
1. 1.19-1.25 d d 6H – CH–(CH3)2
2. 3.23-3.28 m 1H – (CH3)2–CH
3. 3.87 s 3H – O–CH3
4. 6.97-7.46 Overlapped 5H – Ar-H
2d 4H J=7.85,8.70 Ar-H
5. 9.52 s 1H – N–H
N
CH3
CH3
O
NH
O
CH3
N
Cl
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SYTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-3-CYANO-6-
ISOPROPYL-2-METHOXY-5-[N-PHENYL-AMINOCARBONYL]-PYRIDINES.
(A) Synthesis of 4-Methyl-3-oxo-N-phenyl-pentanamide :
           See  Chapter-2, Section-II (A), Page No. 110.
(B) Synthesis of 2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide :
See Chapter-2, Section-II (B), Page No.110.
(C) Synthesis of 3-Cyano-6-isopropyl-2-methoxy-4-phenyl-5[N-phenyl-
aminocarbonyl]-pyridine:
To a solution of  2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide(2.93gm 0.01mol)
and malononitrile (0.60gm, 0.01 mol)  in methanol  add freshly prepared sodium
methoxide solution with stirring, slowly heat the reaction mixture at 50oC for 8hrs., cool
the reaction mixture and pour into the crushed ice. Filter the product and wash with
water dry and purified into ethyl acetate. Yield 57 %  m.p. 143-145oC  Anal.Calcd. for
C23H21N3O2  Calcd: C, 74.37; H, 5.70; N, 11.31 %, Found: C, 74.35; H, 5.67; N,
11.30%.
Similarly, other  4-Aryl-3-cyano-6-isopropyl-2-methoxy-5-[N-phenyl-
aminocarbonyl]-pyridines were prepared. The physical data are recorded in Table No.9.
(D) Biological evaluation of 4-Aryl-3-cyano-6-isopropyl-2-methoxy-5[N-
phenyl-aminocarbonyl]-pyridines:
Antimicrobial activity was carried out as described in Chapter-1, Section-I(D),
Page No. 43. The zones of inhibition of the test solutions are recorded in Graphical
Chart No. 9.
EXPERIMENTAL
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type
(IX) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
It was observed that the compounds showed good activity against Gram
positive bacteria. Maximum activity was observed in compounds having  R=p-
fluorophenyl, phenyl substituents against B.coccus. The compounds bearing bearing R=m-
nitrophenyl, p-flurophenyl, phenyl  have highly inhibited the growth of S.aureus.
Compounds with R=m-nitrophenyl, p-fluorophenyl showed significant activity
against Aerogenes. While the compounds bearing  R=p-fluorophenyl, o-hydroxyphenyl
have fairly inhibited the growth P.aeruginosa.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
All the compounds were active against A.niger. Maximum activity was observed by the
compounds bearing R=m-nitrophenyl, p-chlorophenyl.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug Griseofulvin.
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SYTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL- 3-CYANO-2-
ETHOXY-6-ISOPROPYL-5-[N-PHENYL-AMINOCARBONYL]-PYRIDINES.
SECTION - II
Cyanopyridines play a vital role owing to their range of biological and
physiological activites. In the light of these biological activities and variety of industrial
applications, some new  cyano ethoxy pyridine derivatives of Type (X) have been
prepared by the condensation of 3-Aryl-2-isobutanoyl-N-phenyl-acrylamide with
malononitrile and sodium ethoxide.
N
CH3
CH3
O
NH
O
R
N
CH3
Type (X) R= Aryl
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
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Reaction Scheme
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Alkane C – H str.(asym.) 2960.1 2975-2950 A
–CH3 C – H def. (asym.) 1433.0 1470-1435 "
–CH2 C – H str. (sym.) 2852.5 2870-2845 "
C – H (scissoring) 1483.2 1480-1440 "
–C (CH3)2 C – H def. 1382.9 1390-1360 "
Aromatic =C – H str. 3039.3 3080-3030 "
C = C str 1608.6 1612-1600 "
1585.5 1585-1573 "
C – H i.p. (def) 1271.0 1269-1247 "
1180.4 1181-1171 "
C – H o.o.p. (def) 799.7 832-802 "
Pyridine C = C str. 1633.6 1680-1580 "
C=N str. 1585.4 1580-1550 "
Carboxamide C =O 1676.0 1680-1630 "
N – H str. 3298.0 3380-3150 "
Nitrile C=N str. 2220.1 2240-2220 "
Chloride C-Cl str 752.2 800-600 "
Ether C-O-C 1253.6 1200-1260
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
IR SPECTRAL STUDIES OF 4-(p-CHLOROPHENYL)-3-CYANO-2-ETHOXY-6-ISOPROPYL-5-[N-
PHENYL-AMINOCARBONYL]-PYRIDINE.
N
CH3
CH3
O
NH
O
CN
Cl
CH3
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NMR SPECTRAL STUDIES OF 4-(p-CHLOROPHENYL)-3-CYANO-2-ETHOXY-6-ISOPROPYL-
5-[N-PHENYL-AMINOCARBONYL]-PYRIDINE.
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (400 MHz)
Signal
No.
Multiplicity J. value
in Hz
Signal Position
(δ ppm)
Relative No.
of Protons Inference
1. 1.12-1.15 d,d 6H – CH–(CH3)2
2. 1.41-1.44 t 3H _ -CH2-CH3
3. 3.12-3.20 m 1H – (CH3)2–CH
4. 4.01-4.06 q 2H CH3-CH2
5. 7.10-7.64 Overlapped 5H – Ar-H
2d 4H J=8.10, 8.70 Ar-H
6. 8.98 s 1H – N–H
N
CH3
CH3
O
NH
O CH3
Cl
N
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EXPERIMENTAL
SYTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL- 3-CYANO-2-
ETHOXY-6-ISOPROPYL-5-[N-PHENYL-AMINOCARBONYL]-PYRIDINES.
(A) Synthesis of 4-Methyl-3-oxo-N-phenyl-pentanamide :
           See  Chapter-2, Section-II (A), Page No. 110.
(B) Synthesis of 2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide :
See Chapter-2, Section-II (B), Page No.110.
(C) Synthesis of  3-Cyano-2-ethoxy-6-isopropyl-4-phenyl-5-[N-phenyl-
aminocarbonyl]-pyridine :
To a solution of 2-Isobutanoyl-3-phenyl-N-phenyl-acrylamide(2.93gm 0.01mol)
and malononitrile (0.60gm, 0.01 mol)  in absolute ethanol add freshly prepared solution
of sodium ethoxide  in absolute ethanol.Slowly heat the reaction mixture with stirring at
50oC for 8hrs., cool the reaction mixture and pour into the crushed ice. Filtered the
product and washed with water, dried and recrystalized in ethyl acetate. Yield 57 %
m.p. 187-189oC  Anal.Calcd. for C24H23N3O2     Calcd: C, 74.78; H, 6.01; N, 10.90 %,
Found: C, 74.; H, 5.97; N, 10.89%.
Similarly,  other 4-Aryl-3-cyano-2-ethoxy-6-isopropyl-5-[N-phenyl-
aminocarbonyl]-pyridines were prepared. The physical data are recorded in Table No.10.
(D) Biological  evaluation of 4-Aryl-3-cyano-2-ethoxy-6-isopropyl-5-[N-
phenyl-aminocarbonyl]-pyridines:
Antimicrobial activity was carried out as described in Chapter-1, Section-I(D),
Page No. 43. The zones of inhibition of the test solutions are recorded in Graphical
Chart No.10.
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type (X)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=p-
fluorophenyl, p-methylphenyl, o-hydroxyphenyl substituents against B.coccus. The
significant activity was observed in compounds bearing R=p-chlorophenyl,
p-methylphenyl, m-phenoxyphenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R=p-fluorophenyl,
p-methoxyphenyl, m-phenoxyphenyl against Aerogenes. In case of P.aeruginosa all
the compounds were least active except R=p-fluorophenyl, p-chlorophenyl,
o-hydroxyphenyl.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However significant activity was shown by the compounds bearing R=p-chlorophenyl,
p-fluorophenyl, p-hydroxy-m-methoxyphenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug  Griseofulvin.
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INTRODUCTION:
Quinolines are an important class of heterocyclic therapeutic agents. Quinolines
are the most widely studied nucleus particularly in the diseases like antibacterial1, anti-
fungal2, antimalarial3, antitumor4 and also in antiinflammatory5. In past the search for
synthetic antimalarial other than quinine derivatives initiated in Germany early in the twen-
tieth century. It was based on the observations of Guttman and Ehrlich6 made in 1891
that the dye methylene blue had some chemotherapeutic effect on malarial patients. These
observations laid the stone for synthetic antimalarial. In 1920’s the first synthetic anti-
malarial agent, pamaquine was synthesized by Schulemann et al.7, which is 8-amino quino-
line derivative.
To get more effective and safe antimalarial compounds, a large series of 4-amino
quinolines investigated as a part of the extensive cooperative program in the USA during
second world war. In 1943, Chloroquine eventually proved most promising drug.
The quinoline nucleus occurs in several natural compounds (cinchona alkaloids)
and pharmacologically active substances displaying a broad range of biological activ-
ity.8-10 In addition to the medicinal applications, quinolines have been employed in the
study of bioorganic and bioorganometallic processes.11-13
SYNTHETIC ASPECT:
The literature survey reveals that several named organic reactions, publications
and patents described the synthesis of quinolines some are as under.
1. Skraup quinoline synthesis.14
Quinoline from aniline, glycerole, sulphuric acid and oxidizing agent.
NH2
OH
OH
OH Con H2SO4
Ph NO2
+
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2. Combes quinoline synthesis.15
Acid catalyzed condensation of aniline and β-diketones to assemble quinolines.
NH2 N
R2
R1
Con H2SO4+
R1
O
R2
O
3. Conrad-Limpach reaction16
Thermal or acid-catalyzed condensation of aniline and β-ketoester leads to
quinolin-4-one.
NH2 N
H
O
R1
+
R1
O
O
O
Et
Ph2O
260 oC
4. Friedlander synthesis17
Quinoline synthesis from the Condensation of o-amino benzaldehyde with α-
methylene carbonyl compound.
NH2
CHO
N R1
O
O
Et
+
R1
O
O
O
Et
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5. Pfitzinger quinoline synthesis18.
Quinoline-4-carboxylic acid from the condensation of  isatic acid and α-methyl
ene carbonyl compound using base.
N
H
O
O
N R1
R2
COOH
R1
O
R2+
6. Doebner reaction.19
The preparation of substituted cinchonic acid by the condensation of an ary
lamine, aliphatic or aromatic aldehyde and pyruvic acid is known as the Doebner
reaction.
NH2
+
CH3
COOH
O
CH3
O
Ph
N Ph
7. Doebner-Von Miller synthesis.20
The α,β unsaturated aldehyde like crotonaldehyde reacts with aromatic amine to
yield quinoline derivatives.
NH2
+
N CH3
H
O
CH3
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8. Gould-Jacobs reaction.21
Synthesis of 4-hydroxyquinoline by the action of alkoxymethylenemalonic ester
or acylmalonic ester on arylamine is known as Gould-Jacob reaction.
NH2
+
N
OH
EtO H
O
OEt
O
EtO
9. Knorr Quinoline synthesis.22
The construction of 2-hydroxyquinoline or 2-quinolone by the treatment of β-
keto ester with aryl amine above 100oC is regarded as Knorr quinoline
 synthesis. The intermediate anilide undergoes cyclodehydration with concen
trated sulphuric acid.
NH2
+
N
CH3
OH
O
OEt
O
CH3
NH O
O
CH3
Con H2SO4
N
H
CH3
O
10. Niementowski Quinoline synthesis.23
Synthesis of 4-hydroxyquinoline by the action of carbonyl compound on anthra
nilic acid is referred as a Niementowski quinoline synthesis.
NH2
COOH
+
N
OH
R1
R2
R2
O
R1
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REACTION MECHANISM
Reaction mechanism of the Friedlander synthesis.
The Friedlander annulation, among the other methods, is one of the most simple
and straight forward approaches for the synthesis of quinoline derivatives.
The mechanistic pathway of the ordinary Friedlander synthesis is not rigorously
known. Two steps are formulated. In  first step a condensation reaction, catalyzed by
acid or base, takes place, that can lead to formation of two different types of products:
(a) an imine (Schiff ’s base) (I), or (b) an α,β-unsaturated carbonyl compound (II).
Although that reaction has been known for more than one hundred years, it is not clear
whether the reaction proceeds via pathway (a) or (b) or both. Since the reaction works
with a large number of different substrates and under various reaction conditions, e.g.
catalyzed by acid or base, or without catalyst, it is likely that the actual mechanistic
pathway varies with substrate and reaction conditions.24 The next step in both the cases
are dehydrative cyclization to yield the quinoline (III).
NH2
O
R
+ R2
O
R1
O
R
N
R1
R2
NH2
R
R2
R1
O
(a) (b)
N
R
R1
R2
(I)
(II)
(III)
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Reaction mechanism of the Knorr Quinoline synthesis.
The mechanism involves two steps. In first step the amino group reacts with β-
keto ester to furnish the anilide and in second step cyclization of anilide in the presence
of acid by the loss of water molecule to afford quinoline derivative.
NH2 H5C2O O
CH3
O
NH
O-
OC2H5
CH3
O
..
H+
NH O
CH3
OH +
..
N+ O
CH3OH
H
H
H+
N+ O
CH3OH2 +
H
H
H
N O
CH3
H
-EtOH
-H2O
..
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THERAPEUTIC IMPORTANCE
It is well-known that the quinoline skeleton plays an important role as an
intermediate for the design of antitumor, antimalarial, antiviral, antibacterial and
antiinflammatory agents.25-28 The quinolines are found to be a basic structural unit of
several bioactive molecules.29-31 Camptothecin32,33 and leuotonins34 are the anticancer
and antiinflammatory compounds respectively having this unit.
The chemical properties of quinoline and its derivatives have been widely dis-
cussed because of their biological relevance, coordination capacity and their use as
metal extracting agent.35 They have attracted special interest due to their therapeutic
properties. On the other hand quinoline sulphonamides have been used in treatment of
cancer, tuberculosis and malaria.36
Several quinoline derivatives possess chemotherapeutic activity and act as
antimalarial and antiallergic agents.37 They show broad spectrum efficiency against
multiple herpes viruses and they have a potential role for the treatment of a variety of
infections.38  8-Hydroxyquinoline is one of the most important derivatives of quinoline.
8-Hydroxyquinoline and its derivatives have high antibacterial activities.39-40 Some of
the 8-hydroxyquinoline derivatives and their complexes with transition metals were
reported to  active against some bacteria.41
Considerable interest has been around in the chemistry of quinoline due to its
wide spectrum  of biological activities described as under.
1. Antihypertensive.42
2. Bacteriocidal.43-45
3. Analgesic.46,47
4. Antidepressant.48
5. Herbicidal.49,50
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6. Anticonvulsant.51
7. Antitumor.52,53
8. Antidiabetic.54
9. Antiulcer. 55
10. Antiinflammatory. 56
11. Anticancer. 57
12. Antimalarial.58
Alexander Levitzki, et al59  synthesized  potent inhibitors of platelet-derived growth
factor receptor tyrosine kinase: structure-activity relationships in quinolines (IV).
N Cl
O
O
CH3
CH3
Dwight Macdonald, et al60 synthesized the quinoline derivatives (V) and evaluated
for their phosphodiesterase (PDE4) inhibitors. Michael J. Coghlan, et al61 described
The synthesis and  biological activity of the novel quinolines(VI) was prednisolone-
equivalent in whole cell assays of glucocorticoid function.
N
H
CH3
CH3
O
Cl
CH3(VI)
N
N
N3
(IV)
(V)
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Synthesis, biological evaluation and SAR dependencies for a series of novel 2,5-
dioxo-2,5-dihydro-1H-pyrrolo- [3,4-c]quinoline derivative (VII) inhibitors of caspase-
3 are described by Alexandre V. Ivachtchenko.62
N
S
O
O
N
NH
N
O
O
AcO
CH3
Multiparallel  amenable synthesis of 6-Methoxy-8-amino-4-oxo-1,4
dihydroquinoline-2-[N-(p-(morpholin-4-yl)phenyl)]carboxamides (VIII) and 4,8-
Diamino-6-methoxy-quinoline-2-[N-(p-(morpholin-4-yl)phenyl)]carboxamides(IX)
which are described by Carey L. Horchler et al.63 The resulting novel series were
determined to contain potent 5HT1B antagonists.
N
R''R'
N
O
N
O
NHN
R1 R2
O
CH3
N
O
N
H
O
NH
N
R1 R2
O
CH3
O
(VIII)
(IX)
Discovery of phenyl acetic acid substituted quinolines (X) as novel liver X receptor
agonists for the treatment of atherosclerosis have been reported by Baihua Hu and co
worker.64
(VII)
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N
CF3
O
COOH
In quest to search antibacterial and antimalarial compounds, researchers have
synthesized many 2-quinolone compounds. Its derivatives are available in natural prod-
ucts in abundance. The potential application of  quinones in certain malaria and cancer
chemotherapy encouraged Pettit R. George65 to extend his studies on 8-hydroxy
carbostyryl derivatives. In 1962, 2 and 4-quinolone derivatives (XI to XIII) were pat-
ented by Imperial Chemicals Ltd.66 which were tested for β-adrenergic blocking agents
and found to be effective.
NH
CH3 CH3
N
OH
O
CH3
OH
NH
CH3 CH3
N
O
CH3
N
OH
NH CH3
CH3
O
CH3
Dereck Buckle and coworkers67 synthesized many 4-hydroxy-2-quinolones ana-
logs substituted at 3-position with nitro group(XIV) and they compared antiallergic ac-
tivity with their related hetero aromatic analogs.
(X)
(XI) (XII) (XIII)
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 (XIV)
N
CH3
O
NO2
OH
Uchida et al.68 in 1983 synthesized quenolone derivative (XV) which are useful
for curing peptic ulcer of stomach and duodenum. The compound named Rebamipide
particularly has prophylaxis and curing effects for treating chronic ulcers.
N
H
COOH
N
H
O
Cl
O
Hasegawa et al.69 had prepared 2-quinolones platinum complexes(XVI) which
are useful for treating a malignant tumor.
N O
O
R
O
CH3
Pt+
OH -
(XV)
(XVI)
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potent orally active, nonsteroidal androgen receptor agonist (XVII) were
discovered by Lawrence G. Hamann, et al.70
N
H
N
H
O
CF3
CH3
Atwal and coworkers71 serendipitously observed that pyranoquinoline (XVIII)
of type below possess pure calcium channel blocking activity.
N O
O
N
O
OH
CH3CH3
El-Taweel and group72 have synthesized poly substituted quinolines (XIX, XX)
of  following structures evaluated for bactericidal activity against both Gram negative
and Gram positive bacteria.
(XVII)
(XVIII)
N
CH3
O
N
NH2
CN
N
CH3
O
O
O
N
CH3
S N
O
(XIX) (XX)
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Novel 4-Aryl-3-hydroxyalkyl-quinoline-2-one derivatives (XXI) were prepared
by Piyasena Hewawasam, et al73 and evaluated as openers of the cloned maxi-K channel
relaxants of corporal smooth muscle for erectile dysfunction.
N
H
O
(CH2)n
OHOH
Cl
F3C
(XXI)
Quinoline ring system is a very active heterocyclic system in existing drugs, It
passeses various types of activity like Antimalarial, Antispasmodic,Coronary vasodilator,
etc. Many natural occuring drugs are also having quinoline moiety. Therefore it was
considered worthwhile to synthesise some quinoline derivatives to get compounds having
better therapeutic activity which have been described as under.
SECTION-I    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-
( p-FLUOROPHENYL)-2-ISOPROPYL-3- [N-ARYL-
AMINOCARBONYL]-QUINOLINES.
SECTION-II    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-
I S O P R O P Y L -5 , 6 , 7 , 8 -SUBSTITUTED QUINOLINE-
2(1H)-ONES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(p-FLUOROPHENYL)-
2-ISOPROPYL-3-[N-ARYL-AMINOCARBONYL]-QUINOLINES.
Quinoline derivatives have remarkable therapeutic activity. Taking this
consideration, we have undertaken the preparation of quinoline derivatives. The
preparation of the 4-(p-Fluorophenyl)-2-isopropyl-quinoline-3-N-aryl-carboxamide of
Type (XI)  have been carrie out by the condensation of 2-Amino-4’-fluoro-benzophenone
with 4-Methyl-3-oxo-N-aryl-pentanamide in the presence of methane sulphonic acid.
N
F
CH3
CH3
NH
O
R
Type (XI) R= aryl
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
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Reaction Scheme
CH3
CH3
O
OMe
O
+
CH3
CH3
O
O
NHR +
Toluene
R= Aryl
NH2
O
F
N
F
CH3
CH3
NH
O
R
methan sulphonic acid
NH2
R
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IR SPECTRAL STUDIES OF 4-(p-FLUOROPHENYL)-2-ISOPROPYL-3[N-PHENYL-
AMINOCARBONYL]-QUINOLINE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2971.4 2975-2950 108
–CH3 C – H str. (sym.) 2873.0 2880-2860 "
C – H def. (asym.) 1445.7 1470-1435 "
–C (CH3)2 C – H def. 1380.5 1390-1360 "
Aromatic =C – H str. 3067.8 3080-3030 "
C = C str 1600.9 1612-1600 "
1402.2 1417-1401 "
C – H i.p. (def) 1255.7 1269-1247 "
1019.4 1018-1008 "
C – H o.o.p. (def) 810.1 832-802 "
Quinoline C=N str. 1562.6 1580-1550 110
Carboxamide C =O 1645.3 1680-1630 "
N – H str. 3224.1 3380-3150 "
Chloride C-F str 1095.6 1110-1000 "
N
CH3
CH3
NH
O
F
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NMR SPECTRAL STUDIES OF 4-(P-FLUOROPHENYL)-2-ISOPROPYL-3[N-PHENYL-
AMINOCARBONYL]-QUINOLINE.
N
CH3
CH3
NH
O
F
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (400 MHz)
Signal
No.
Multiplicity J. value
in Hz
Signal Position
(δ ppm)
Relative No.
of Protons Inference
1. 1.398-1.381 d 6H – CH–(CH3)2
2. 3.424-3.374 m 1H – (CH3)2–CH
3. 6.959-8.023 Overlapped 5H – Ar-H
2d 4H J=8.72, 7.68 Ar-H
4H – Qn-H
4. 9.850 s 1H _ NH
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(p-FLUOROPHENYL)-
2-ISOPROPYL-3-[N-ARYL-AMINOCARBONYL]-QUINOLINES.
(A) Synthesis of 4-Methyl-3-oxo-N-phenylpentanamide:
           See  Chapter-2, Section-II (A), Page No.110.
(B) Synthesis of  4-(p-Fluorophenyl)-2-isopropyl-3[N-phenyl-aminocarbonyl]-
quinoline :
To the mixture of  2-Amino-p’-fluoro benzophenone(2.15gm 0.01mol) and 4-
Methyl-3-oxo-N-phenylpentanamide(2.05gm, 0.01mol) in benzene, add methane
sulphonic acid till acidic pH obtained. Reflux the reaction mixture and remove water by
azeotropically by Dean & Stark. Cool the reaction mixture and add water to the reaction
mixture, adjust pH 9-10 of the reaction mixture using caustic solution, separate the  layer
and distill out benzene under vacuum. The residue was recrystallized in  isopropyl alcohol.
Yield 60% M.P.. 223-225oC Anal. Calcd. for  C25H21FN2O Calcd: C, 78.10; H, 5.51;
N, 7.29 %, Found: C, 78.08; H, 5.47; N, 7.28%.
Similarly, other 4-(p-Fluorophenyl)-2-isopropyl-3-[N-aryl-aminocarbonyl]-
quinolines were prepared. The physical data are recorded in Table No.11.
(C) Biological  evaluation of  4-(p-Fluorophenyl)-2-isopropyl-3-[N-aryl-
aminocarbonyl]-quinolines:
Antimicrobial activity was carried out as described in chapter-I, Section-I (D),
Page No. 43. The zones of inhibition of the test solutions are recorded in Graphical
chart No. 11.
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type
(XI) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
Maximum activity was observed in compounds bearing R=p-fluorophenyl, p-
methoxyphenyl, p-methylphenyl, m-methoxyphenyl substituents against B.coccus  and
R=p-fluorophenyl, p-nitrophenyl, p-methoxyphenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R=m-nitrophenyl,
o,p-dichlorophenyl, m,p-dichlorophenyl and phenyl against Aerogenes. In case of
P.aeruginosa all the compounds were least active except R=o,p-dichlorophenyl, m,p-
dichlorophenyl and phenyl.
ANTIFUNGAL  ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
It has been concluded that all the compounds were active against A.niger.Maximum
activity was displayed by the compounds bearing  R=p-fluorophenyl,m,p-dichlorophenyl
and phenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug Griseofulvin.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ISOPROPYL-
5,6,7,8-SUBSTITUTED QUINOLINE-2(1H)-ONES.
Quinoline derivatives represent one of the most active classes of compounds
having a wide spectrum of biological activities. Looking to the interesting properties of
quinoline it was considered worthwhile to synthesize a series of quinoline of Type-(XII)
for obtaining biologically potent agents which were prepared by the cyclisation of  4-
Methyl-3-oxo-N-aryl-pentanamide by concentrated sulphuric acid.
SECTION - II
N
H
O
CH3CH3
R2
R1
R3
R4
Type (XII)
R1,R2,R3,R4= H, NO2,
Cl, CH3, OCH3 ...
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger  at a concentration of 40μg. The biological activities
of synthesized compounds were compared with standard drugs.
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CH3
CH3
O
OMe
O
NH2
R1
R2
R3
R4
+
CH3
CH3
O
O
NH
R1R2
R3
R4
Toluene
R1,R2,R3,R4 =  H,CH3, OCH3, 
N
H
CH3CH3
O
R1
R2
R3
R4
Con. sulphuric acid
Cl, Br, NO2,F
Reaction Scheme
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quinolone
N
H
CH3CH3
O
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2952.0 2975-2950 108
–CH3 C – H str. (sym.) 2875.7 2880-2860 "
C – H def. (asym.) 1435.9 1470-1435 "
–C (CH3)2 C – H def. 1381.9 1390-1360 "
Quinoline C=C 1590.2 1680-1580 110
C –N str. 1286.4 1300-1200 "
C =O 1651.0 1680-1630 "
N – H str. 3268.2 3380-3150 "
IR SPECTRAL STUDIES OF 4-ISOPROPYL QUINOLIN-2(1H)-ONE.
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NMR SPECTRAL STUDIES OF 4-ISOPROPYL QUINOLIN-2(1H)-ONE.
N
H
CH3CH3
O
1. 1.27-1.24 d 6H CH–(CH3)2
2. 3.48-3.37 m 1H (CH3)2–CH
3. 6.35-7.84 Overlapped 5H Qn-H
4. 11.61 s 1H N–H
Internal Standard : TMS; Solvent : DMSO   : Instrument : GEMINI-2000 Spectrometer (200 MHz)
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons Inference
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m/z = 187
C+
N
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m/z = 172
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ISOPROPYL-
5,6,7,8-SUBSTITUTED QUINOLINE-2(1H)-ONES.
(A) Synthesis of 4-Methyl-3-oxo-N-phenylpentanamide :
           See  Chapter-2, Section-II (A), Page No. 110.
(B) Synthesis of  4-Isopropyl quinoline-2(1H)-one :
 A mixture of 4-Methyl-3-oxo-N-phenylpentanamide (2.05gm, 0.01mol) and
concentrated sulphuric acid was heated to 60-70oC for 5hrs. cool the reaction mixture
and slowly pour into the crushed ice, extract the product with dichloromethane. Distilled
out dichloromethane the resulting residue was solidify with n-Hexane and purified in
ethyl acetate the Yield 30% M.P.. 180-182oC Anal. Calcd. for  C12H13NO Calcd: C,
76.98; H, 7.00; N, 7.48 %, Found: C, 76.95; H, 6.97; N, 7.46%.
Similarly, other 4-Isopropyl-5,6,7,8-substituted quinoline-2(1H)-ones were
prepared. The physical data are recorded in Table No.12.
(C) Biological evaluation of 4-Isopropyl-5,6,7,8-substituted quinoline-2(1H)-
ones :
Antimicrobial activity was carried out as described in chapter-I, Section-I(D),
Page No. 43. The zones of inhibition of the test solutions are recorded in Graphical
Chart No. 12.
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RESULTS AND DISCUSSION
ANTIBACTERIAL  ACTIVITY
It has been observed from the experimental data that all compounds of Type
(XII) were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing
R2=fluoro,chloro,nitro and R2,R3=dichloro substituents against B.coccus. The significant
activity was observed in compounds bearing R2=bromo R3=nitro, R2,R3=dichloro
R2,R4=dichloro against S.aureus.
The maximum act iv i ty  was  d isp layed by the  compounds  bear ing
R2=fluoro,bromo,nitro R3=methoxy against Aerogenes. In case of P.aeruginosa all the
compounds were least active except  R2=fluoro,bromo,chloro  R2,R3=dichloro.
ANTIFUNGAL   ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However significant activity was shown by the compounds bearing R2=nitro R2,R3=nitro
against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin,Ciprofloxacin,Erythromycin and antifungal activity was compared with
standard drug Griseofulvin.
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INTRODUCTION
In the last few years Microwave induced Organic Reaction Enhancement (MORE)
chemistry has gained popularity as a non-conventional technique for rapid organic
synthesis & many researchers have described accelerated organic reaction and a large
number of papers have appeared proving the synthetic utility of MORE chemistry in
routing organic synthesis. It can be termed as “e-chemistry” because it is easy, effective,
economical and eco-friendly and is believed to be a step towards green chemistry.
High speed microwave synthesis has attracted a considerable amount of attention
in recent years. The first report on the use of microwave heating to accelerate organic
chemical transformations by the groups of Gedye and Giguere/Majetich in 1986.
Microwave assisted organic chemistry has experienced exponential growth since mid-
1990.
Microwave heating is very efficient energy source and can be used to significantly
reduce reaction time of numerous organic reactions. It allows preparation of numbers of
compounds at the same time in microwave cavity. Therefore it is very useful in parallel
synthesis and combinatorial synthesis. Moreover, can lead to improve isolated yields
compared to conventional technology. Microwave assisted organic synthesis [MAOS]
provides an efficient alternative for the synthetic chemist.
Microwave heating is distinguished primarily by being a radiant process. Its
relationship to ordinary heat is of much interest. Regular heat rays differ in frequency
and properties. In the conventional method, heat is generated by molecular collisions
which accomplish the energy transfer while microwaves cause heating through the
absorption of energy quanta. Microwave generate instantaneous “ incore” heating of
materials, in a homogeneous and selective manner, especially those with poor heat
conduction properties.
The microwave region of the electromagnetic spectrum lies between 1 cm and
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1 m and in order to avoid interfering with radar and telecommunication activities which
operate within this region, most domestic and commercial microwave instruments operate
at 2.45 GHz. The heating effect utilized in microwave assisted organic transformations is
due in the main, to dielectric polarization, although conduction losses can be important
particularly at higher temperatures. Whilst the polarizability of a molecule (determined
by the Debye equation) is the sum of a number of contributions, only dipolar and interfacial
polarization are important to heating effects associated with microwave irradiation.
Mechanism :
The mechanisms associated with microwave heating are dipole rotation and ionic
conduction. When a molecule is irradiated with microwaves it will attempt to align itself
with the electric field by rotation. If the frequency of molecular rotation is similar to the
frequency of microwave radiation (2.45GHz), the molecule will continuously align and
realign itself with the oscillating field, therefore the electric energy is absorbed by the
molecule. It is obvious that compounds with large dielectric constants tend to absorb
energy readily under microwave irradiation. The interfacial polarization, the Maxwell-
Wagner effect, may also contribute to the heating effect when the conducting particles
are in contact with a non conducting medium, e.g. in heterogenous reactions. It is
particularly convenient that qualitatively the larger the dielectric constant, the greater
the coupling with microwaves. Thus solvents such as water, methanol, DMF, ethyl acetate,
chloroform, acetone, acetic acid, dichloromethane and R-spirit are all heated when
irradiated with microwaves. Nonpolar solvents like CCl4, toluene, xylene, diethylether
do not couple and therefore do not heat with microwave irradiation.
APPLICATIONS IN ORGANIC SYNTHESIS
The first application of microwave ovens in organic synthesis began very recently.
In the first experiment, Gedye1 and then Giguere2, provided evidence for dramatic
accelerations in some classical organic reactions and these were ascribed to temperature
and pressure effects, when performed in closed teflon vessels. Since solvents were used
in these experiments, some problems with safe operation appeared and explosions
sometimes resulted. Further developments demonstrated the potential of solvent free
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reactions to solve these problems and to facilitate the scale up of preparative runs.
Recently, reactions under dry conditions using inorganic reagents are gaining more
attention because of their enhanced selectivity and milder conditions than those associated
with conventional homogeneous reaction procedures. It should be noted that some of
the inorganic additives reach temperatures in excess of 1000oC very rapidly and
decomposition of materials may be problematic, therefore some precautions regarding
super heating and associated fire hazards or explosions are taken.
Three types of solvent free procedures can be coupled with microwave activation.
(i)  Reactions between heat reactants, needing at least one polar molecule, as liquid-
 liquid or liquid solid systems. In this later case, reactions presumably occur at
 the interface due to absorption of the liquid reactant at the surface of the solid
 one.
(ii)  Reactions between supported reagents on solid mineral supports in dry  media
 by impregnation of compounds on alumina, silicas or clays.
(iii)  Phase Transfer Catalysis (PTC) conditions in the absence of organic solvent,
 i.e. when a liquid reagent acts both as a reactant and an organic phase. This last
methodology can also be improved under sonochemical activation.
Microwave heating has emerged as a powerful technique to promote a variety of
chemical reactions.3-7 Microwave reaction under solvent-free conditions are attractive
in offering reduced pollution and offer low cost together with simplicity in processing
and handling.8-11 The recent introduction of microwave synthesis has gained acceptance
and popularity among the synthetic chemist community & it includes virtually all types of
chemical reactions such as Diels-Alder12, Claisen13, Vilsmeier14, Oxidation15,
Substitution16-17,  Cyclisation18-19,  Catalytic hydrogenation20-21,  Knoevenagel
condensation22, oxime synthesis23, alkylation24-26, decarboxylation27 etc. Malhotra V. et.
al.28 have demonstrated one-pot condensation of chalcones with thiosemicarbazide in
ethanol under strongly basic condensation. Microwave enhanced esterification of α,β
unsaturated acids have been carried out by Kumar Mitra & coworkers29. Microwave
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assisted  1,2,4-triazines, 1,2,4-tetrazoles, pyrazoles and triazoles have been synthesized
by Mazaahir Kidwai & co-workers30. Microwave assisted Pall-Knorr condensation was
carried out by G. Minetto& co-workers.31 Some other organic synthesis like 1,4-
dihydropyridines32, phthalimide33 & quinazolinone34 derivatives etc. also enhanced by
the microwave irradiation.
Recently, microwave assisted some new organic reactions have been carried out
which include synthesis of pyrazolines35,36, isoxazoles37, cyanopyridines38, quinoxalines
and heterocyclic pyrazines39, N-aryl phtalamic acids40, substituted 2-pyridones41,
sulfonylbenzimidazole-4,7 diones42, aminopyridines43, iminobenzotriazoles44,
arylamines45, dihydropyrimidines.46
Microwave assisted chemical reactions are gaining importance due to advantages
and environmentally friendly process they offer as compared to conventional reactions.
As a part of ongoing research towards the nontraditional approach to the experimental
setup of organic reaction, the concept of microwave enhanced reaction has been utilized
for rapid and efficient synthesis of 4-Aryl-6-isopropyl-5-[N-(p-nitrophenyl)
aminocarbonyl]-3,4-dihydropyrimidine-2(1H)-ones and 4-Aryl-6-isopropyl-5-[N-(p-
nitrophenyl)aminocarbonyl]-3,4-dihydropyrimidine-2(1H)-thiones. Q. Pro-M microwave
oven is used as a microwave irradiation source and compared in terms of yield and
reaction period and have been cited in Table No. 13 and 14.
SECTION-I :  MICROWAVE ENHANCED SYNTHESIS OF 4-ARYL-6-
I S O P R O P Y L - 5 - [ N - ( p - N I T R O P H E N Y L )
AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-
ONES.
SECTION-II : MICROWAVE  ENHANCED  SYNTHESIS OF 4-ARYL-6-
I S O P R O P Y L - 5 - [ N - ( p - N I T R O P H E N Y L )
AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-
THIONES.
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SECTION-I
O
NH
O
CH3
CH3
O2N
+
O
R
NH2
NH2 O
NH
N
H
O
R
CH3
CH3
O
NH
O2N
Con HCl, methanol
Microwave irradiation
          4-6 Min.
The constitution of the synthesized products have been characterized by using
elemental analyses, Infrared and 
1
H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
The compounds of  Type (I) have been already synthesized using conventional
method as reported earlier in Chapter-1, section-III (B), Page No. 64.
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation  source
and data are compared in terms of yield and reaction period have been cited in Table
No. 13.
    Type - (I)   R = Aryl
MICROWAVE ENHANCED SYNTHESIS OF 4-ARYL-6-ISOPROPYL-5-[N-(p-
NITROPHENYL)AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-
ONES.
As microwave used to create effect in organic synthesis, the “in situ” generation
of heat is very efficient and can be used to significantly reduce reaction times of
synthetically useful organic transformations. Thus microwave assisted organic synthesis
has advantages over conventional technology. We have synthesized dihydropyrimidinones
of Type (I) by the condensation of 4-Methyl-N-(p-nitrophenyl)-3-oxo-pentanamide, urea
and aryl aldehydes under microwave irradiation in few minutes.
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TABLE No. 13   : COMPARISION OF CONVENTIONAL METHOD AND
MICROWAVE METHOD OF 4-ARYL-6-ISOPROPYL-5-
[ N - ( p - N I T R O P H E N Y L ) A M I N O C A R B O N Y L ] - 3 , 4 -
DIHYDROPYRIMIDINE-2(1H)-ONES.
1a C6H5-- 10 45 4 61 229
1b 4-CI-C6H4- 10 41 5 50 260
1c 2-CI-C6H4- 13 48 5 55 256
1d 4-F-C6H4- 16 47 6 55 250
1e 2-OH-C6H4- 15 51 5 57 231
1f 4-OH-3-OCH3-C6H3- 18 37 4 49 250
1g 4-CH3-C6H4- 11 36 4 59 241
1h 4-OCH3-C6H4- 14 47 6 61 238
1i 3,4-(OCH3)2-C6H3- 10 39 6 60 248
1j 4-NO2-C6H4- 12 41 5 42 251
1k 3-NO2-C6H4- 11 34 5 45 242
1l 3-O-C6H5-C6H4- 15 35 4 55 234
Comp.
No.
ThermalR Microwave
Reaction
Period (hr.)
Reaction
Period (min.)
Yield
%
M.P.
o CYield
%
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SECTION-II
MICROWAVE  ENHANCED  SYNTHESIS OF 4-ARYL-6-ISOPROPYL-5-[N-
(P-NITROPHENYL)AMINOCARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-
THIONES.
As a part of our research program towards the non traditional approach to the
experimental set up of organic reactions, the concept of “Microwave induced Organic
Reaction Enhancement” (MORE) chemistry has been utilized for rapid and efficient
synthesis of some dihydropyrimidine thiones of Type (II) which is described as under.
The synthesis was carried out by condensation of 4-Methyl-N-(p-nitrophenyl)-3-oxo-
pentanamide, thiourea and aryl aldehydes under microwave irradiation for few min.
O
NH
O
CH3
CH3
O2N
+
O
R
NH2
NH2 S
NH
N
H
S
R
CH3
CH3
O
NH
O2N
Con HCl, methanol
Microwave irradiation
          4-8 Min.
Type - (II) R = Aryl
The constitution of the synthesized products have been characterized by using
elemental analyses, Infrared and 
1
H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
The compounds of  Type (II) have been already synthesized using conventional
method as reported earlier in Chapter-1, section-II (B), Page No. 54.
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation  source
and data are compared in terms of yield and reaction period have been cited in Table
No. 14.
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TABLE No. 14   : COMPARISION OF CONVENTIONAL METHOD AND
MICROWAVE METHOD OF 4-ARYL-6-ISOPROPYL-5-[N-
( p - N I T R O P H E N Y L ) A M I N O C A R B O N Y L ] - 3 , 4 -
DIHYDROPYRIMIDINE-2(1H)-THIONES.
1a C6H5-- 12 47 6 62 247
1b 4-CI-C6H4- 18 45 5 52 233
1c 2-CI-C6H4- 15 50 7 59 241
1d 4-F-C6H4- 17 47 8 54 267
1e 2-OH-C6H4- 16 52 6 60 251
1f 4-OH-3-OCH3-C6H3- 13 55 6 63 244
1g 4-CH3-C6H4- 18 35 5 50 259
1h 4-OCH3-C6H4- 15 39 4 57 242
1i 3,4-(OCH3)2-C6H3- 14 45 7 60 235
1j 4-NO2-C6H4- 17 42 6 52 274
1k 3-NO2-C6H4- 16 44 8 48 255
1l 3-O-C6H5-C6H4- 12 48 8 53 260
Comp.
No.
ThermalR Microwave
Reaction
Period (hr.)
Reaction
Period (min.)
Yield
%
M.P.
o CYield
%
CONCLUSION
We have demonstrated a rapid and general synthesis of dihydropyrimidinone and
dihydropyrimidine thions using a microwave oven. Microwave technology is emerging
as an alternative energy source powerful enough to accomplish chemical transformation
in minutes, instead of hours. Consequently, reactions exhibit cleaner products and more
facile work-up procedures. For this reason, microwave irradiation is presently seeing
an exponential increase in acceptance as a technique for enhancing chemical
synthesis.Moreover, it can lead to improve isolated yields compared to conventional
technology.
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